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Abstract 
With the aim to develop a specific radioligand for imaging the cyclic nucleotide 
phosphodiesterase 5 (PDE5) in brain by positron emission tomography (PET), seven new 
fluorinated inhibitors (3 – 9) were synthesized on the basis of a quinoline core. The inhibitory 
activity for PDE5 together with a panel of other PDEs was determined in vitro and two 
derivatives were selected for IC50 value determination. The most promising compound 7 (IC50 
= 5.92 nM for PDE5A), containing a 3-fluoroazetidine moiety, was further radiolabeled by 
aliphatic nucleophilic substitution of two different leaving groups (nosylate and tosylate) using 
[18F]fluoride. The use of the nosylate precursor and tetra-n-butyl ammonium [18F]fluoride 
([18F]TBAF) in 3-methyl-3-pentanol combined with the addition of a small amount of water 
proved to be the best radiolabeling conditions achieving a RCY of 4.9 ± 1.5% in an automated 
procedure. Preliminary biological investigations in vitro and in vivo were performed to 
characterize this new PDE5 radioligand. Metabolism studies of [18F]7 in  mice revealed a fast 
metabolic degradation with the formation of radiometabolites which have been detected in 
the brain.  
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1. Introduction 
 
The cyclic nucleotide phosphodiesterases (PDEs) are a large family of enzymes that regulate 
intracellular levels of the two important second messengers cyclic adenosine 3’,5’-
monophosphate (cAMP) and cyclic guanosine 3’,5’-monophosphate (cGMP) by cleavage of 
their phosphodiester bond. To date, 11 subtypes of these enzymes have been identified and 
classified mainly according to their amino acid sequences. Phosphodiesterase 5 (PDE5) is 
specific for cGMP which is generated by the nitric oxide (NO)-dependent soluble guanylate 
cyclase and activates the protein kinase G (PKG). PKG activation triggers phosphorylation of 
numerous intracellular proteins that in turn regulate many primary physiological functions 
such as modulation of vascular tone and vasorelaxation in vascular smooth muscle. This was 
the basis for the breakthrough of one of the most celebrated PDE5 inhibitors namely sildenafil 
(Viagra®) which is used as treatment for erectile dysfunction and chronic pulmonary 
hypertension. Moreover, currently this enzyme arouses increasing interest of clinical 
researchers as a multifunctional biomarker and drug target because PDE5 inhibition also 
affects neurodegenerative [1] and cancerous processes [2]. For example, increased PDE5 
levels have been reported in several carcinomas including colon adenocarcinoma, bladder 
squamous carcinoma, thyroid tumors, metastatic breast, prostate, pancreatic, bladder and 
lung cancers [3-9]. As it was demonstrated, that cGMP can reduce cell growth and induce 
apoptosis [10, 11], and that PDE5 catalyzes the degradation of cGMP, this enzyme has been 
suggested to be involved in tumor progression because its elevation goes along with 
increasing tumor grade and stage [4, 12]. Moreover, PDE5 inhibitors are able to enhance the 
chemotherapeutic efficacy of anticancer drugs in different tumors and cancer cell types [9, 
13-15] and inhibition of PDE5 has an impact on the attenuation of multidrug resistance, one 
of the major causes of unsuccessful anticancer treatments [16, 17]. 
Despite the tremendous growth of preclinical and clinical studies on the use of PDE5 inhibitors 
and their promising results, the mechanisms of action are in most cases not fully understood 
and detailed insights are needed. For example, the currently available data are insufficient to 
make any conclusive statement regarding the exact role of the PDE5 enzyme in cancer 
pathogenesis [12, 18]. 
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The aim of our research is the development of a PDE5-specific radioligand to support in vitro 
and in vivo studies on the investigation of pathology-specific changes in the availability of the 
enzyme using PET. Regarding tumor imaging, those studies would enable the assessment of 
the spatiotemporal pattern of PDE5 expression. Thereby, our particular interest is dedicated 
to a future investigation of brain tumors by characterizing the expression of PDE5 in healthy 
and diseased brain.  
In recent years, several attempts have been made to develop PET radioligands targeting the 
PDE5 enzyme as reviewed elsewhere [19, 20]. Most of the radiotracers are labeled with 
carbon-11 and suffer from a lack of specificity [21, 22]. Chekol et al. reported on the 
development of fluorine-18 labeled PDE5 radioligands [23, 24]. In particular a vardenafil-
based derivative showed a high retention in the lungs which was interpreted to be PDE5-
specific because of the high expression of PDE5 in this organ [23]. Biodistribution studies in 
mice showed that none of the ligands investigated in this study demonstrated significant brain 
uptake. By contrast, a recent report by the same group revealed that a pyridopyrazinone 
based 18F-labeled derivative has shown accumulation in rat brain. Although the radiotracer 
readily entered the brain, the radioactivity uptake was not specific toward PDE5. On the other 
hand, this compound demonstrated specific binding in transgenic mice with cardiomyocyte-
specific PDE5 overexpression [24].  
Searching for a suitable lead compound for the development of a brain penetrating PDE5 
radioligand, we decided to focus our attention on the heterocyclic quinoline based 
compounds 1 and 2 (Figure 1). These derivatives were described with a high PDE5 potency 
and the potential to cross the blood-brain barrier [25, 26]. Structure-activity relationship 
studies (SAR) revealed important structural features of this family of PDE5 inhibitors [25, 26]. 
The quinoline scaffold bearing a hydroxymethyl group at position C-3 (“east region”) improves 
the inhibitory activity on PDE5 and the solubility compared to the other core ring systems 
tested. The binding to the protein is highly dependent on the presence of the secondary amino 
functionality at position C-4 (“north region”) [27]. Moreover, the influence of a combination 
of different substituents on positions C-6 and C-8 of the quinoline scaffold was studied 
resulting in the so far most potential candidates 1 [25] and 2 [26]. Based on these results, we 
started our attempts to introduce a fluorine containing structural moiety at the "east region" 
of 1 and 2 by substituting the hydroxymethyl group on C-3 by a fluoroethyl and 
fluoroethoxymethyl group [28], resulting in the development of the new PDE5 radioligand 
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[18F]ICF24027 [29]. However, due to the fast formation of a brain-penetrable radiometabolite, 
this radiotracer was not suitable for PDE5 imaging in brain. The aim of the present study was 
to investigate the possibility of introducing fluorine containing moieties at the "north" or 
"south region" (position 4 or 8) of the quinoline scaffold (Figure 1) in order to develop a 
specific and metabolically more stable 18F-labeled radioligand for imaging of the PDE5 enzyme 
in brain. 
 
2. Results and discussion 
2.1. Ligand development 
2.1.1. Concept 
For introduction of the fluorine atom at the "north region" of the lead structures 1 and 2, 
modification of the chlorobenzene scaffold was intended (Figure 1). As the secondary amine 
substituted at the C-4 position of the quinoline core is known to be crucial for the PDE5 
inhibitory activity [27], it was not considered for an alkylation with a fluorinated alkyl side 
chain. In order to enable a straightforward radiofluorination, the substitution of a 2-fluoro-3-
methoxypyridine ring was favored (3 and 4). This strategy allows nucleophilic heteroaromatic 
substitution with [18F]fluoride using synthetic easily accessible halogen or nitro substituted 
precursor compounds [30]. 
Structural modifications performed at the "south region" of the lead compound 1 usually have 
a minor impact on the PDE5 inhibitory activity [26]. Therefore, we selected four structurally 
diverse moieties to introduce the fluorine at the C-8 position of the quinoline core by 
substituting the ethyl group of 1 as follows (Figure 1): (i) fluoropropyl alkyl chain (5), (ii) 4-
fluoropiperidine (6) and (iii) 3-fluoroazetidine (7) as aliphatic rings and (iv) 2-fluoropyridines 
(8 and 9) as aromatic rings. 
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Figure 1. Design of fluorinated compounds with introduction of the fluorine atom on substituents located at C-4 
or C-8 position of the quinoline core of the lead compounds 1 and 2. 
 
2.1.2. Organic Chemistry  
The synthesis of derivatives 3 and 4 bearing modifications in the "north region" of the 
quinoline scaffold, started with the coupling of amine 10a with the 4-chloroquinoline 11 via 
aromatic nucleophilic substitution at the C-4 position of the quinoline ring (Scheme 1). 4-
Chloroquinoline 11 was prepared as previously described by our group [28]. The necessary 
amine 10a was synthesized in 5 steps according to known procedures (see supporting 
information). The resulting derivative 12 was further functionalized at the C-8 position via a 
Suzuki-Miyaura cross-coupling reaction with commercially available ethylboronic or 
cyclopropylboronic acid to generate 13a and 13b with a yield of 68% and 86%, respectively. 
The desired fluorinated compounds 3 and 4 were obtained by a selective reduction of the ester 
function with lithium tri-tert-butoxyaluminum hydride (LTBA). 
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Scheme 1. Synthesis of "north region" compounds 3 and 4.  
Reagents and conditions: (a) 10a, N,N-diisopropylethylamine (DIPEA), n-propanol, reflux, 2 h; (b) ethylboronic 
acid for 13a and cyclopropylboronic acid for 13b, Pd(PPh3)4, Cs2CO3, toluene, reflux, 15-22 h; (c) LTBA, THF, 50 °C, 
30 h.  
 
For the synthesis of compounds 5-9 modified at the C-8 position of the quinoline core, two 
different palladium-catalyzed reaction pathways were developed in order to form the C-C bond 
in 5 and the C-N bond in 6-9 starting from compound 14 [28]. The synthesis of 5 started with 
the reaction of allyl alcohol with 9-borabicyclo[3.3.1]nonane (9-BBN) in tetrahydrofuran to 
afford the corresponding boronic ester, generated in situ at the α-position of the alkene 
reactant. This complex was used directly for the subsequent Suzuki-Miyaura cross-coupling 
reaction with 14 (Scheme 2, strategy 1) to afford the alcohol 15 with a yield of 26%. It is worth 
mentioning, that the concomitant formation of the debrominated analog of 14 was observed 
in a ratio of about 1/1. 
To further convert the alcohol function into fluorine, 15 was treated by diethylaminosulfur 
trifluoride (DAST) under classical conditions. However, the formation of the desired fluorinated 
product 16 could not be observed and only a by-product, identified as compound 17, was 
obtained with a yield of 57%. We assume that the formation of this stable six-membered ring 
in 17 is a result of an intramolecular cyclization caused by the electron donor effects of the 
free secondary amine located at the C-4 position of the quinoline, as previously observed 
during the chemical modifications at the "east region" of this compound class [28]. Therefore, 
an alternative strategy (Scheme 2, strategy 2) was developed, in which the amine at the C-4 
position of 14 was beforehand protected using di-tert-butyl dicarbonate (Boc2O) in the 
presence of catalytic amounts of N,N-4-dimethylaminopyridine (DMAP) to obtain 18 with a 
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yield of 74%. For the following Suzuki-Miyaura coupling at C-8 position, a fluorinated boronic 
ester was used, generated from the reaction of allyl bromide with tetra-n-butylammonium 
fluoride (TBAF) and 9-BBN. Thus, the fluoroalkylated compound 19 was successfully 
synthesized and used in the next synthesis step without further purification. Finally, the ester 
group was converted into the corresponding alcohol to obtain 20 which was treated with 
trifluoroacetic acid (TFA) to remove the Boc protecting group resulting in the desired derivative 
5 with a yield of 31%. 
 
Scheme 2. Synthesis of "south region" compound 5. 
Reagents and conditions: (a) 1) Allyl alcohol, 9-borabicyclo[3.3.1]nonane (9-BBN), THF, 0 °C → rt, 7 h; 2) 
Pd(PPh3)4, K2CO3, H2O, DMF, 80 °C, 22 h; (b) Diethylaminosulfur trifluoride (DAST), CH2Cl2, -60 °C  → -30 °C, 2 h; 
(c) (Boc)2O, DMAP, Et3N, THF, rt, 2.5 h; (d) 1) Allyl bromide (reagent and solvent), TBAF, rt, 30 min; 2) 9-BBN, 
THF, -10 °C → rt, 7 h; 3) Pd(PPh3)4, K2CO3, H2O, DMF, 80 °C, 16 h; (e)LTBA, THF, 60 °C, 20 h; (f) TFA/CH2Cl2, 1/2, 
v/v, rt, 3 h. 
 
For the synthesis of compounds 6-9 via C-N bond formation at the C-8 position of compound 
14 (Scheme 3), the Buchwald-Hartwig coupling reaction was used. Therefore, 14 was treated 
with commercially available 4-fluoropiperidine, 3-fluoroazetidine and the synthesized 
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pyridines 10a, b (see supporting information) to afford 21a-d in 56-93% yields. Further 
reduction of the ester function to the corresponding alcohol with LTBA provided the desired 
fluorinated compounds 6-9.  
 
 
Scheme 3. Synthesis of "south region" compounds 6-9. 
Reagents and conditions: (a) 4-fluoropiperidine hydrochloride for 21a, 3-fluoroazetidine hydrochloride for 21b, 
10a for 21a and 10b for 21b, Pd(OAc)2, BINAP, Cs2CO3, toluene, 120 °C, 3 h for 21a and b, 16 h for 21c and 4 h for 
21d; (b) LTBA, THF, 60 °C, 20 h. 
 
2.2. Determination of inhibitory activity 
The inhibitory potential of the new fluorinated derivatives 3-9 on the human recombinant 
PDE5A1 protein and selected other human PDEs were evaluated by using an enzyme assay 
[31] with sildenafil as standard reference compound. The tests were performed at two 
different concentrations of the compounds; 100 nM for PDE5A1 and 1.0 µM for the other 
PDEs. The results are summarized in Table 1. Analyses of the data revealed a considerable 
decrease of PDE5A1 potency for derivatives 3 and 4 (34.6 and 20.9% of inhibition, respectively) 
compared to the lead compounds 1 and 2 (90.3 and 84.2%, respectively). Hence, the 
substitution of the 3-chloro-4-methoxy phenyl ring by a 2-fluoro-3-methoxy pyridine ring in 
the "north region" of the molecule is unfavorable for binding to the PDE5A1 protein. By 
contrast, derivatives 5–9 are characterized by structural modifications in the "south region" 
at C8 of the quinoline core. Although the introduced motifs are structurally quite diverse, their 
influence on the inhibitory activity toward the PDE5A1 is rather low and the obtained values 
do not differ considerably compared to 1 and 2. This is in accordance with the results reported 
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by Fiorito et al. [26], who also modified the functionalities at the C8-position. All new 
derivatives 3-9 demonstrated a high selectivity for the PDE5 enzyme as shown by the weak 
inhibitory potential against PDE2A3, PDE3A, PDE4A1 and C2, PDE6AB, PDE9A1, PDE10A1, and 
PDE11A1 at 1 µM concentrations. 
As derivatives 6 and 7 showed the highest inhibition values for PDE5A1, they were selected 
for determination of IC50 values by measuring the inhibition at seven different concentrations 
(0.25 – 1000 nM) [31]. With an IC50 value of 5.92 nM compound 7 showed the highest 
inhibitory potential which is comparable to sildenafil (IC50 = 6.23 nM). Although the inhibitory 
activity of 7 is slightly lower compared to our first developed radiotracer [18F]ICF24027 [28, 
29], this compound demonstrated a good selectivity toward the other PDEs and was therefore 
selected for 18F-labeling to generate a potential radiotracer for PET imaging of PDE5A. 
 
Table 1. Percentage inhibition values of synthesized compounds against selected PDEs 
Comp. 
Percentage of inhibition (%) IC50(PDE5A1) 
(nM) PDE2A3a PDE3Aa PDE4A1a PDE4C2a PDE5A1b PDE6ABa PDE9A1a PDE10A1a PDE11A1a 
1c 22.4 NI 45.4 40.9 90.3 49.8 NI 40.0 27.2  
2c 15.3 NI 36.9 22.4 84.2 32.4 NI 22.9 24.1  
3 10.4 NI 33.4 4.52 34.6 35.9 2.87 27.9 11.8 n.d. 
4 14.1 NI 22.2 15.9 20.9 23.2 NI 15.8 8.80 n.d. 
5 16.0 NI 37.3 18.6 80.7 NI NI 46.8 16.4 n.d. 
6 17.0 NI 36.8 35.3 87.8 24.7 20.6 17.4 23.7 25.6 
7 18.9 NI 18.3 16.1 90.3 10.8 8.71 23.5 13.2 5.92 
8 76.6 NI 28.6 15.3 64.2 13.9 23.4 17.2 8.82 n.d. 
9 39.5 NI 24.5 18.7 80.5 5.79 NI 21.0 11.2 n.d. 
ICF24027c 7.49 18.2 9.03 32.4 88.4 60.4 NI 14.1 5.21 1.86 
Sildenafilc 67.7 63.9 65.8 55.4 86.7 65.7 74.0 74.6 78.5 6.23 
 
a The compounds were tested at 1 µM against PDE2A3, PDE3A, PDE4A1, PDE4C2, PDE6AB, PDE9A1, 
PDE10A1 and PDE11A1 and b at 100 nM against human PDE5A1. NI means no inhibition; n.d. means not 
determined. c Own reported data [28]. 
 
2.3. Precursor synthesis and radiochemistry 
For the synthesis of the new radioligand [18F]7, the aliphatic nucleophilic substitution reaction 
of a precursor with a suitable leaving group by [18F]fluoride was intended. As 18F-labeling of 
an azetidine ring was only described in a single report [32], and the radiolabeling at a 
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secondary carbon atom is usually more challenging than on a primary carbon atom [33], we 
investigated the use of two sulfonate leaving groups with different reactivity. Therefore, the 
precursor molecules 27 and 28 with methylbenzenesulfonate (tosylate) and 4-
nitrobenzenesulfonate (nosylate), respectively, were synthesized. According to the literature, 
the nosylate is known to be slightly more reactive than tosylate [34, 35]. 
Based on former experiments with this compound class (data not shown), the alcohol 
functionality was not protected as its acidity is expected to be too low to considerably 
influence the radiolabeling reaction.  
 
2.3.1. Synthesis of the precursor compounds 
The precursor compounds 27 and 28 were prepared as shown in Scheme 4. In a first step, the 
ester function of 14 was reduced to the corresponding alcohol 22, which was further protected 
as a silyl ether group to give 23. As described above for compound 21b, the azetidine moiety 
was then coupled on the C-8 position of the quinoline core of derivative 23 using freshly 
prepared azetidin-3-ol trifluoroacetate [36] to produce compound 24 with a yield of 51%. 
Afterwards, the tosylation and nosylation reactions were performed under classical conditions 
to afford 25 and 26, respectively. Finally, the triisopropyl silyl (TIPS) protecting group was 
cleaved in the presence of TBAF to afford the desired tosylate 27 and nosylate 28 precursors 
with yields in the range of 60-70%. 
 
 
 
Scheme 4. Synthesis of precursor compounds 27 and 28 for 18F-radiolabeling. 
Reagents and conditions: (a) LTBA, THF, 60 °C, 20 h, (b) TIPSCl, Et3N, DMAP, DMF, rt, 36 h, (c) azetin-3-ol 
trifluoroacetate, Cs2CO3, 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (BINAP), Pd(OAc)2, toluene, reflux, 3 h, (d) 
TsCl for 25 or NsCl for 26, Et3N, DMAP, DCM, rt, 19 h, (e) TBAF, THF, rt, 30 min. 
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2.3.2. Radiosyntheses 
2.3.2.1. Methylbenzenesulfonate (OTs) as leaving group 
The 18F-labeling of the tosylate precursor 27 was investigated with the conventional potassium 
carbonate (K2CO3) - kryptofix-222 system (K[18F]F/K222 complex) changing different reaction 
parameters (solvents, temperatures and reaction times). When the reaction was performed 
in acetonitrile (ACN) at 90 °C and in DMF at 130 or 150 °C, only the formation of by-products 
could be observed. Using DMSO at 130 °C resulted in the generation of [18F]7 with a 
radiochemical yield of 2 - 3% after 5 min (determined by radio TLC of a sample of the reaction 
mixture). However, the RCY decreased with increasing reaction time indicating a 
decomposition of the radiotracer. The same effect was observed for the precursor 27 itself, 
which was entirely decomposed after 15 min reaction time according to HPLC analysis, 
probably due to a competing ß-elimination reaction. Further investigations revealed that 100 
°C was the optimal temperature for this radiolabeling system resulting in RCYs of 3 - 4% after 
15 min (Scheme 5). The reactions were performed with a precursor amount of 2.0 - 2.5 mg; 
higher concentrations of 27 did not result in an increase of RCY. Due to the presumed base 
sensitivity of both, the precursor and the radiotracer, potassium oxalate as less basic counter 
ion was tested in combination with K222 in DMSO. However, these conditions did not lead to 
the formation of [18F]7. Moreover, we tested [18F]TBAF as a mild nucleophilic 18F-fluorination 
agent in tert-amyl alcohol, as previously used by Zhang et al. for radiolabeling of the same 
azetidine motif in a PDE2A radioligand [32]. However, in contrast to the reported results (RCY 
of 7.3% at the end of the synthesis) we could not obtain the desired radiotracer [18F]7 under 
these conditions. 
Finally, it turned out that using the K[18F]F/K222 complex in DMSO was most useful for the 
synthesis of [18F]7 on the basis of a tosylate precursor and was therefore translated to an 
automated procedure using the TRACERlab FX2 N synthesis module (GE Healthcare). The 
synthesizer setup is described in the experimental part. Briefly, after trapping and elution of 
[18F]fluoride by an aqueous potassium carbonate solution from an anion exchange cartridge, 
the labeling reaction of the azeotropically dried K[18F]F/K222 complex with the precursor 27 
was performed in DMSO for 15 min at 100 °C. For isolation of [18F]7, the crude reaction mixture 
was diluted with aqueous acetonitrile and directly applied to a semi-preparative HPLC system 
(chromatogram in supporting information). The radiotracer fraction was collected at a 
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retention time of 22 - 24 min and purified by solid phase extraction (SPE) using a C18-cartridge. 
The obtained radiotracer eluate was transferred out of the hot cell, concentrated and 
formulated in sterile isotonic saline containing 10% of ethanol. In a total synthesis time of 80 
min, [18F]7 could be reproducibly produced with a high radiochemical purity of ≥ 99%, a 
radiochemical yield of 2.5 ± 0.1% (n = 3) and molar activities between 14 and 28 GBq/µmol (n 
= 3, end of synthesis EOS) with starting activities of 4 - 5 GBq. Co-injection of the corresponding 
reference compound 7 confirmed the identity of [18F]7 by analytical radio-HPLC 
(chromatogram in supporting information).   
 
2.3.2.2. 4-Nitrobenzenesulfonate (ONs) as leaving group 
For 18F-labeling of the nosylate precursor 28 we started as for the tosylate by using the 
K[18F]F/K222 complex. Reactions were performed in ACN, DMF and DMSO at different 
temperatures (90 °C for ACN, 130 and 150 °C for DMF and DMSO, resp.) resulting in RCYs lower 
than 1%. Moreover, the tertiary alcohols tert-BuOH and 3-methyl-3-pentanol (3M3P) were 
tested, because nonpolar protic solvents are described to be beneficial for aliphatic 
nucleophilic substitution [37, 38] as e.g. reported for [18F]FLT [39, 40] and [18F]FES [41]. 3-
Methyl-3-pentanol (3M3P) was recently used by Marchand et al. [40] because of its high 
boiling point of 123 °C avoiding an excessive pressure in the reactor. For the [18F]FLT synthesis, 
the ratio of nosylate precursor to base was also shown to be crucial for the labeling process 
[40, 42]. In the presence of an excess amount of base, the precursor is undergoing an E2 
elimination mechanism, thus reducing the desired nucleophilic 18F-fluorination [42]. 
Therefore, we started with a constant precursor to base ratio of 1.5 using 4 mg of precursor 
28 and 0.6 mg of K2CO3 as base. While reaction in tert-BuOH at 95 °C resulted in an RCY of 2%, 
a higher RCY of 7% could be achieved in 3M3P at 125 °C. With the aim to minimize the amount 
of precursor used, we further investigated the 3M3P system and found that a minimal ratio of 
0.75 (2 mg precursor and 0.6 mg base) is necessary to achieve this RCY. However, when 
transferring this procedure to an automated process, we observed an insufficient elution of 
[18F]fluoride from the anion exchange cartridge with this low amount of base. To reduce the 
loss of activity on the cartridge to a minimum of 10%, 1.2 mg of K2CO3 has been found to be 
necessary in our automated system, which would result in the undesired use of higher 
precursor amounts.  
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Because of the observed base sensitivity of the nosylate precursor 28, [18F]TBAF was also 
investigated as fluorination agent. While in DMSO no radiolabeling could be obtained, an RCY 
of up to 10% was found in 3M3P at 125 °C with 2 mg of 28. By chance we observed that small 
amounts of water favored this radiolabeling reaction. The presence of water in 18F-fluorination 
reactions can positively influence the RCY as already described by different groups [43, 44] 
and has been explained with the dependence of the nucleophilicity of fluoride by its hydration 
state [45, 46]. Indeed, in our system the addition of 50 – 100 µL water to the reaction mixture 
(total volume 1 mL) increased the RCY up to 20% (Scheme 5). However, the addition of more 
water lead to a reduction of the RCY. Attempts to skip the azeotropic drying step by eluting 
the [18F]fluoride with tetra-n-butylammonium hydrogen carbonate (TBAHCO3) dissolved in the 
radiolabeling solvent 3M3P and 100 µL water failed due to the immiscibility of this tertiary 
alcohol and water.  
Finally, the conditions were applied to an automated procedure using the TRACERlab FX2 N 
module. The detailed procedure is described in the experimental part. Briefly, after trapping 
on an anion exchange cartridge, the [18F]fluoride was eluted with TBAHCO3 dissolved in an 
ACN/water solution and the resulting [18F]TBAF was dried by azeotropic distillation. The 
radiolabeling reaction was performed after addition of the nosylate precursor 28 dissolved in 
3M3P/ACN/water (700/200/80, v/v/v) for 10 min at 125 °C. For isolation of [18F]7 with semi-
preparative HPLC, the solvent was removed under reduced pressure because a strong peak 
broadening was observed when the tertiary alcohol remained in the injection solution. After 
evaporation, the crude reaction mixture was diluted with aqueous acetonitrile and applied to 
a semi-preparative HPLC system (chromatogram in supporting information). The radiotracer 
fraction was collected at a retention time of 26 - 29 min and purified by solid-phase extraction 
(SPE) using a C18 cartridge. The obtained radiotracer eluate was transferred out of the hot 
cell, concentrated and formulated in sterile isotonic saline containing 10% of ethanol. The 
entire process for this radiosynthesis lasted about 85 min. Finally, [18F]7 could be reproducibly 
produced with a high radiochemical purity of ≥ 99%, a radiochemical yield of 4.9 ± 1.5% (n = 
3) and molar activities between 28 and 58 GBq/µmol (n = 3, EOS) with starting activities of 4 - 
5 GBq. The identity of [18F]7 was confirmed by analytical radio-HPLC (chromatogram in 
supporting information).   
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Scheme 5. 18F-Labeling procedures developed with the tosylate and nosylate precursors (27 and 28) to 
radiosynthesize the new PDE5 radioligand [18F]7. 
 
The stability of the radiotracer was investigated by incubation at 40 °C in phosphate-buffered 
saline (PBS) and pig plasma samples. [18F]7 proved to be stable in these media, and no 
defluorination or degradation was observed within 60 min of incubation time. 
 
2.4. In vitro autoradiographic studies of [18F]7 on porcine brain 
To investigate the distribution of binding sites of [18F]7 in brain, in vitro autoradiographic 
studies on porcine brain slices were performed. The most dense binding was detected in the 
fornix (Fx), followed by corpus callosum (CC) and thalamus (Th). Although in human, PDE5 
expression was demonstrated in cerebellum (Cb), cortex (Cx), and hippocampus (Hip) [47], 
only modest levels of binding were observed for [18F]7 on these structures of the porcine 
brain.  
To investigate the specificity of [18F]7 binding, blocking studies with co-incubation of 1 µM of 
7 or 1 µM of sildenafil were performed (data in Figure 2). Only a slight decrease of [18F]7 
binding in the range of 10-25% for all of the investigated brain regions was observed indicating 
a high non-specific binding of the radiotracer. This high non-specific binding has also been 
observed for our previously reported PDE5 radioligand [18F]ICF24027  and we assumed it could 
be related to its high lipophilicity (logD of 3.9 calculated using ACD/Labs) [29]. However, in 
comparison to [18F]ICF24027, the hydroxyl group of [18F]7 is non-alkylated resulting in a 
calculated logD value of 1.56. Thus, the high non-specific binding might be caused by other 
properties. Probably with an IC50 value of 5.92 nM as a measure of the inhibitory potential, 
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the actual affinity of [18F]7 is still too low for a specific imaging of PDE5 as recently discussed 
by P. Cumming [48]. Based on an estimation of Bmax values in certain brain regions, the author 
proposed the need of ligands with sub-nanomolar affinity to achieve a binding potential 
suitable for PET imaging.  
 
 
 
Figure 2. Binding of [18F]7 (2.02 ± 0.75 nM) in porcine brain in vitro (n=3). Remaining binding of [18F]7 in the 
presence of 1 µM 7 or 1 µM sildenafil is presented as percentage of total binding (= 100%). Abbreviations: Acb = 
Nucleus accumbens, Cb = Cerebellum, CC = Corpus callosum, Cd = Nucleus caudatus, CS = Colliculus superior, Cx 
= Cortex, Fx = Fornix, Hip = Hippocampus, Th = Thalamus. 
 
2.5 In vivo studies of [18F]7 in mouse 
2.5.1. Organ uptake  
For mouse brain, we determined standard uptake values (SUV) of 1.10 (n=1) and 0.08 (n=2; 
single values: 0.10 and 0.05) at 5 and 30 min, respectively, after injection of [18F]7, which 
indicate perfusion-mediated uptake of the radioligand in the brain followed by a relatively fast 
washout of the activity. In periphery, we could detect the high initial uptake in organs with 
comparatively high expression of PDE5 such as lung (SUV = 8.70 and 0.98 at 5 and 30 min p.i.) 
and heart (SUV = 5.00 and 0.48 at 5 and 30 min p.i.) [49]. Although it might be assumed that 
the herein observed order of late-stage SUV with lung > heart > brain (0.98, 0.48, 0.08 at 30 
min p.i.) in CD1 mouse indeed correlates with the reported mRNA levels in rabbit [49], this 
assumption remains to be investigated. 
 
2.5.2. Metabolism studies 
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In vivo metabolism of [18F]7 was studied in CD-1 mice (n = 2) by investigation of plasma and 
brain samples obtained from at 30 min after injection of the radioligand. Analysis of the 
samples was performed by the use of micellar chromatography (MLC) and RP-HPLC. MLC 
allows the direct injection of samples into the HPLC system without eliminating the tissue 
matrix due to the ability of micellar aggregates to dissolve the proteins and other components. 
For RP-HPLC analysis proteins were precipitated by treating aliquots of plasma and brain 
homogenates with a mixture of acetone/water, resulting in recoveries of about 97% of activity 
in the supernatants. 
The results obtained with both methods correlated very well. According to the 
chromatograms (Figure 3), a high fraction of radiometabolites was detected in plasma with 
only 13% of total radioactivity representing the nonmetabolized radioligand [18F]7. Several 
radioactive metabolites were observed and we assume that some of them are brain 
penetrable as they were also observed in the corresponding brain samples. Thus, only 24% of 
total activity was represented by intact [18F]7 in brain (Figure 3). In particular, the more 
lipophilic radiometabolite [18F]M4 seems to easily penetrate the blood-brain barrier and 
accumulates in the brain. By contrast, the metabolites group [18F]M1 is very polar as the 
species are eluting without significant retention on the hydrophobic HPLC column. Despite 
this polarity, they were also detected in the brain samples to a considerable amount (Figure 
3). We assume that this group of radiometabolites consists of small molecular weight species 
containing alcohol, aldehyde or acid functions which might be formed due to N-dealkylation 
of the azetidine ring. However, as the radioligand described herein doesn't show the potential 
for future use, we didn't characterize the structure of the radiometabolites. 
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Figure 3. Exemplary MLC (A) and RP-HPLC (B) radio-chromatograms of a mouse plasma and brain sample at 30 
minutes p.i. of [18F]7 (conditions MLC: Reprosil-Pur C18-AQ, 250 x 4.6 mm, gradient with an eluent mixture of 
THF/100 mM SDS/10 mM Na2HPO4 aq., 1.0 mL/min; conditions RP-HPLC: Reprosil-Pur C18-AQ, 250 x 4.6 mm, 
gradient with an eluent mixture of ACN/20 mM NH4OAc aq., 1.0 mL/min) 
 
3. Summary and conclusion 
Continuing our efforts in the development of PET imaging probes for characterization of the 
expression pattern of the cyclic nucleotide phosphodiesterase PDE5 in brain, we synthesized 
a series of fluorinated derivatives based on a quinoline lead compound (1). While structural 
modification in the "east and west regions" of 1 have been already investigated by our group 
[28], the present study was dedicated to modifications in the "north and south regions" of 1. 
Substitution of a 2-fluoro-3-methoxypyridine ring in the "north part" of 1 caused a loss of 
inhibitory potential on PDE5. By contrast, the "south part" of 1 is less restricted for structural 
modifications resulting in the potential 3-fluoroazetidine containing derivative 7 with an IC50 
value of 5.92 nM for PDE5 and high selectivity regarding other PDEs.  
As 18F-labeling of a secondary carbon is challenging, two different leaving groups were 
investigated for a nucleophilic aliphatic substitution with [18F]fluoride. Interestingly, highest 
RCY of 4.9 ± 1.5% (EOS) was achieved for automated radiosynthesis of [18F]7 due to the 
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addition of small amounts of water to the reaction mixture of the nosylate precursor in 3-
methyl-3-pentanol and [18F]TBAF. By contrast, using the tosylate precursor and K[18F]F/K222 
complex in DMSO resulted in lower RCY of 2.5 ± 0.1% (EOS). First in vivo studies of [18F]7 in 
mice indicated perfusion-mediated uptake of the radioligand in the brain followed by a 
relatively fast washout of activity. However, investigating the in vivo metabolism of [18F]7 in 
mice disclosed the fast formation of several radiometabolites of which a considerable amount 
has been also detected in the brain. Moreover, in vitro autoradiographic studies in porcine 
brain revealed a high nonspecific binding of [18F]7 which might be related to insufficient 
affinity toward PDE5.  
In conclusion, the results of this study support the assumption that for PET imaging of the 
PDE5 enzyme, specific radioligands with an affinity in the sub-nanomolar range seem to be 
crucial. 
   
4. Experimental section 
4.1 Organic chemistry  
4.1.1 General 
All commercially available reagents and solvents were purchased from the following 
commercial suppliers: Sigma Aldrich, Acros Organics, Carlo Erba, and Alfa Aesar and were used 
without further purification. Room temperature (rt) refers to 20-25 °C. All solvents were dried 
using common techniques. Air and moisture sensitive reactions were carried out under 
anhydrous argon atmosphere. Magnesium sulfate (MgSO4) and sodium sulfate (Na2SO4) were 
used as drying agents. Monitoring of the reaction progress was performed using thin layer 
chromatography (TLC) on silica 60 F254 or alumina gel 60A + F254 plates and visualized with 
UV light (UV lamp Fisher Bioblock Scientific, 365 nm or 254 nm) or with an appropriate staining 
agent. Column chromatography was performed on silica gel (Chromagel 60 ACC, 40-63 µm, 
Carlo Erba Reagents) or on alumina gel (Merck, column chromatographic adsorption analysis 
ACC. to Brockmann, neutral aluminium oxide 90, standardised, 63-200 µm). Uncorrected 
melting points (mp) were measured on an IA9100 Digital Melting Point Apparatus. Infrared 
spectra (IR) were recorded in the range of 4000-600 cm-1 on a Nicolet IS10 with attenuated 
total reflectance (ATR) accessory (ν: stretch, as: asymmetric, s: symmetric, δ: deformation; op: 
out of plane). Nuclear magnetic resonance (NMR) spectra were recorded on a Bruker Avance 
500 instrument (500 MHz for 1H, 125 MHz for 13C), a Bruker Avance 400 instrument (400 MHz 
for 1H, 100 MHz for 13C) or a Bruker Avance 200 instrument (200 MHz for 1H, 50 MHz for 13C). 
All chemical shifts (δ) are reported in parts per million (ppm). Coupling constants (J) are given 
in Hertz (Hz). Spectral coupling patterns are indicated as follow: s: singlet; d: doublet; t: triplet; 
q: quartet; m: multiplet, brt: broad triplet and brs: broad singlet. All new compounds were 
analyzed by HRMS (High-Resolution Mass Spectrometry, Waters® Micromass® Q-Tof micro™ 
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Mass Spectrometer, UCA-START, Clermont-Auvergne University, Clermont-Ferrand, France). 
The isotope peaks for chlorine and bromine atoms are given with their relative intensities. 
 
4.1.2 Syntheses 
 
4.1.2.1. Ethyl 8-bromo-6-cyano-4-[((6-fluoro-5-methoxypyridin-2-
yl)methyl)amino]quinoline-3-carboxylate (12): 
N,N-Diisopropylethylamine (293 mg, 2.32 mmol, 4.0 eq.) and the crude product 10a (550 mg, 
2.85 mmol, 5.0 eq., synthesis in supporting information) were added under stirring to a 
solution of 11 [28] (193 mg, 0.57 mmol, 1.0 eq.) in n-propanol (15 mL). The resulting mixture 
was refluxed for 2 hours. After cooling to rt, water (30 mL) was added. The formed precipitate 
was collected by filtration, washed with ethanol (10 mL) and dried to give the desired product 
(160 mg, 0.35 mmol, 61%) as a white solid. Rf (SiO2, cyclohexane/ethyl acetate, 7/3, v/v): 0.15; 
Mp: 186 ± 1 oC; IR (cm-1)  2241 (νC≡N), 1463 (δCH3), 1173 (νC-O); 
1H NMR (400 MHz, DMSO-d6) 
δ 9.49 (brs, 1H, NH), 8.94 (m, 2H, H2, H5), 8.49 (d, 1H, 3JH7-H5 = 1.5 Hz, H7), 7.65 (dd, 1H, 3JH5’-H6’ 
= 8.1 Hz, 4JH5’-F = 10.5 Hz, H5’), 7.32 (d, 1H, 3JH6’-H5’ = 8.1 Hz, H6’), 4.92 (d, 2H, 3JHd-NH = 5.2 Hz, 
Hd), 4.30 (q, 2H, 3JHb-Hc = 7.1 Hz, Hb), 3.86 (s, 3H, He), 1.29 (t, 3H, 3JHc-Hb = 7.1 Hz, Hc); 13C NMR 
(100 MHz, DMSO-d6) δ 166.7 (Ca), 153.9 (C2), 153.5 (C4), 152.0 (d, 1JC3’-F= 234 Hz, C3’), 148.5 
(C8a), 143.8 (d, 3JC1’-F = 11 Hz, C1’), 141.5 (d, 
2JC4’-F = 25 Hz, C4’), 135.1 (C7), 131.7 (C5), 125.3 (C8), 
123.7 (d, 3JC5’-F = 3 Hz, C5’), 120.9 (d, 
4JC6’-F = 4 Hz, C6’), 119.8 (C4a), 117.8 (CN), 107.3 (C6), 105.4 
(C3), 61.2 (Cb), 56.3 (Ce), 50.4 (Cd), 14.0 (Cc); HRMS (ESI) m/z calculated for C20H1779BrFN4O3 
[M+H]+: 459.0468, found C20H1779BrFN4O3 [M+H]+: 459.0474 (100%); C20H1781BrFN4O3 [M+H]+: 
461.0457 (98%). 
 
4.1.2.2. General procedure for 13a and 13b: 
Under stirring and argon atmosphere, cyclopropylboronic acid (3.0 eq.) or ethylboronic acid 
(16 eq.), tetrakis(triphenylphosphine)palladium(0) (15 mg, 12.9 µmol, 0.06 eq.) and caesium 
carbonate (2.5 eq.) were added to a solution of 12 (1.0 eq.) in anhydrous toluene (10 mL). The 
resulting mixture was refluxed until the TLC monitoring revealed the complete consumption 
of 12 (15 h for 13a and 22 h for 13b). After cooling to room temperature, the solvent was 
evaporated under reduced pressure. The crude product was purified by column 
chromatography to give 13a or 13b as white solid.  
4.1.2.2.1. Ethyl 6-cyano-8-ethyl-4-[((6-fluoro-5-methoxypyridin-2-
yl)methyl)amino]quinoline-3-carboxylate (13a): 
Column chromatography conditions: SiO2, ethyl acetate/cyclohexane, 5/5, v/v; yield: 68% (60 
mg, 0.15 mmol); Rf (SiO2, cyclohexane/ethyl acetate, 6/4, v/v): 0.65; Mp: 152 ± 1 oC; IR (cm-1) 
 2229 (νC≡N), 1687 (νC=O), 1570 (δN-H), 1358 (δCH3), 1283 (νC-O), 1187 (νC-O); 1H NMR (400 MHz, 
CDCl3) δ 9.80 (brs, 1H, NH), 9.21 (s, 1H, H2), 8.39 (d, 1H, 4JH5-H7= 1.7 Hz, H5), 7.64 (d, 1H, 4JH7-H5 
= 1.7 Hz, H7), 7.31 (dd, 1H, 3JH5’-H6’ = 8.0 Hz, 3JH5’-HF = 9.8 Hz, H5’), 7.23 (d, 1H, 3JH6’-H5’ = 8.0 Hz, 
H6’), 4.92 (d, 2H, 3JHd-NH = 5.5 Hz, Hd), 4.39 (q, 2H, 3JHb-Hc = 7.1 Hz, Hb), 3.91 (s, 3H, He), 3.19 (q, 
20 
 
2H, 3JHf-Hg = 7.5 Hz, Hf), 1.40 (t, 3H, 3JHc-Hb = 7.1 Hz, Hc), 1.32 (t, 3H, 3JHg-Hf = 7.5 Hz, Hg); 13C NMR 
(100 MHz, CDCl3) δ 168.0 (Ca), 156.6 (C4), 154.1 (d, 1JC3’-F = 241 Hz, C3’), 152.6 (C2), 151.0 (C8a), 
144.9 (C8), 144.1 (d, 3JC1’-F = 11 Hz, C1’), 142.4 (d, 2JC4’-F = 25 Hz, C4’), 130.1 (C7), 129.7 (C5), 122.3 
(d, 3JC5’-F = 4 Hz, C5’), 119.4 (d, 4JC6’-F = 4 Hz, C6’), 119.1 (CN), 118.7 (C4a), 107.0 (C6), 104.8 (C3), 
61.1 (Cb), 56.3 (Ce), 52.5 (Cd), 24.9 (Cf), 14.3 (Cg), 14.1 (Cc); HRMS (ESI) m/z calculated for 
C22H22FN4O3 [M+H]+: 409.1676, found 409.1657. 
4.1.2.2.2. Ethyl 6-cyano-8-cyclopropyl-4-[((6-fluoro-5-methoxypyridin-2-yl)methyl)amino] 
quinoline-3-carboxylate (13b): 
Column chromatography conditions: SiO2, ethyl acetate/cyclohexane, 4/6, v/v; yield: 86% (80 
mg, 0.19 mmol); Rf (Al2O3, cyclohexane/ ethyl acetate, 5/5, v/v): 0.74; Mp: 155 ± 1 oC; IR (cm-
1)  2226 (νC≡N), 1667(νC=O), 1473 (δCH3), 1198 (νC-O); 1H NMR (400 MHz, CDCl3) δ 9.98 (brs, 1H, 
NH), 9.27 (s, 1H, H2), 8.36 (d, 1H, 4JH5-H7 = 1.4 Hz, H5), 7.29 (m, 2H, H7, H5’), 7.22 (d, 1H, 3JH6’-H5’ 
= 8.1 Hz, H6’), 4.93 (d, 2H, 3JHd-NH = 5.5 Hz, Hd), 4.40 (q, 2H, 3JHb-Hc = 7.1 Hz, Hb), 3.91 (s, 3H, He), 
3.04 (m, 1H, Hf), 1.39 (t, 3H, 3JHc-Hb = 7.1 Hz, Hb), 1.23 (m, 2H, Hg or Hg’), 0.79 (m, 2H, Hg or Hg’); 
13C NMR (100 MHz, CDCl3) δ 167.7 (Ca), 156.8 (C4), 153.1 (d, 1JC3’-F = 241 Hz, C3’), 152.1 (C2), 
144.3 (C8a), 143.7 (2C, C8, C1’), 142.5 (d, 2JC4’-F = 25 Hz, C4’), 128.8 (C5), 126.4 (C7), 122.3 (d, 3JC5’-
F = 4 Hz, C5’), 119.4 (d, 3JC6’-F = 4 Hz, C6’), 118.9 (CN or C4a), 118.5 (CN or C4a), 107.4 (C6), 104.8 
(C3), 61.3 (Cb), 56.3 (Ce), 52.4 (Cd), 14.1 (Cc), 11.3 (Cf), 9.7 (2C, Cg, Cg’); HRMS (ESI) m/z calculated 
for C23H22FN4O3 [M+H]+: 421.1676, found 421.1688. 
 
4.1.2.3. General procedure for 3 and 4: 
 A 1.1 M solution of lithium tri-tert-butoxyaluminum hydride in anhydrous tetrahydrofuran (2.7 
mL, 2.97 mmol, 6.0 eq.) was added to a solution of 13a or 13b (1.0 eq.) in anhydrous 
tetrahydrofuran (15 mL) under stirring and argon atmosphere. The resulting mixture was 
heated at 50 oC for 30 hours. After cooling to room temperature, an 0.1 M aqueous sodium 
hydroxide solution (40 mL) was slowly added under stirring (pH 10-11). The aqueous layer was 
extracted with ethyl acetate (4 x 40 mL). The combined organic layers were washed with brine 
(60 mL), dried over anhydrous magnesium sulfate, filtered and then concentrated under 
reduced pressure. The crude product was purified by chromatography (SiO2, 
ethanol/dichloromethane, 1/9, v/v) to give the desired products 3 (white solid) or 4 (light 
yellow solid). 
4.1.2.3.1. 8-Ethyl-4-[((6-fluoro-5-methoxypyridin-2-yl)methyl)amino]-3-
(hydroxymethyl)quinoline-6-carbonitrile (3):  
Yield: 36% (65 mg, 0.18 mmol); Rf (SiO2, ethanol/dichloromethane, 1/9, v/v): 0.29; Mp: 168 ± 
1 oC; IR (cm-1)  3420 (νN-H), 2228 (νC≡N), 1563 (δN-H), 1479 (δCH3), 1010 (νC-O); 1H NMR (400 MHz, 
DMSO-d6) δ 8.81 (d, 1H, 4JH5-H7 = 1.5 Hz, H5), 8.48 (s, 1H, H2), 7.75 (d, 1H, 4JH7-H5 = 1.5 Hz, H7), 
7.59 (dd, 1H, 3JH5’-H6’ = 8.1 Hz, 4JH5’-F = 10.6 Hz, H5’), 7.53 (t, 1H, 3JNH-Hb = 6.7 Hz, NH), 7.21 (d, 
1H, 3JH6’-H5’ = 8.1 Hz, H6’), 5.36 (t, 1H, 3JOH-Ha = 5.1 Hz, OH), 4.84 (d, 2H, 3JHb-NH = 6.7 Hz, Hb), 4.47 
(d, 2H, 3JHa-OH = 5.1 Hz, Ha), 3.83 (s, 3H, Hc), 3.13 (q, 2H, 3JHd-He = 7.5 Hz, Hd), 1.25 (t, 3H, 3JHe-Hd 
= 7.5 Hz, He); 13C NMR (100 MHz, DMSO-d6) δ 155.2 (C2), 151.9 (d, 1JC3’-F = 236 Hz, C3’), 149.9 
(C4), 148.1 (C8a), 147.5 (d, 3JC1’-F = 11 Hz, C1’), 144.1 (C8), 140.9 (d, 2JC4’-F = 25 Hz, C4’), 127.6 (C7), 
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127.4 (C5), 123.6 (d, 3JC5’-F = 4 Hz, C5’), 119.6 (2C, CN, C4a), 119.2 (d, 4JC6’-F = 4 Hz, C6’), 115.5 (C3), 
106.1 (C6), 59.7 (Ca), 56.2 (Cc), 48.8 (Cb), 24.2 (Cd), 14.8 (Ce); HRMS (ESI) m/z calculated for 
C20H20FN4O2 [M+H]+: 367.1570; found 367.1528. 
4.1.2.3.2. 8-Cyclopropyl-4-[((6-fluoro-5-methoxypyridin-2-yl)methyl)amino]-3-
(hydroxymethyl)quinoline-6-carbonitrile (4): 
Yield: 45% (120 mg, 0.32 mmol); Rf (SiO2, ethanol/dichloromethane, 1/9, v/v): 0.40; Mp: 183 
± 1 oC; IR (cm-1)  2226 (νC≡N), 1542 (δN-H), 1478 (δCH3), 1260 (νC-O), 1036 (νC-O); 1H NMR (400 
MHz, DMSO-d6) δ 8.73 (d, 1H, 4JH5-H7 = 1.4 Hz, H5), 8.51 (s, 1H, H2), 7.58 (dd, 1H, 3JH5’-H6’ = 8.2 
Hz, 4JH5’-F = 10.5 Hz, H5’), 7.50 (t, 1H, 3JNH-Hb = 6.6 Hz, NH), 7.35 (d, 1H, 4JH7-H5 = 1.4 Hz, H7), 7.21 
(d, 1H, 3JH6’-H5’ = 8.2 Hz, H6’), 5.39 (t, 1H, 3JOH-Ha = 5.1 Hz, OH), 4.84 (d, 2H, 3JHb-NH = 6.6 Hz, Hb), 
4.49 (d, 2H, 3JHa-OH = 5.1 Hz, Ha), 3.83 (s, 3H, Hc), 3.13 (m, 1H, Hd), 1.11 (m, 2H, He or He’), 0.85 
(m, 2H, He or He’); 13C NMR (100 MHz, DMSO-d6) δ 155.1 (C2), 151.9 (d, 1JC3’-F = 236 Hz, C3’), 
149.9 (C4), 148.7 (C8a), 147.5 (d, 3JC1’-F = 11 Hz, C1’), 144.4 (C8), 140.9 (d, 2JC4’-F = 25 Hz, C4’), 126.2 
(C5), 123.5 (d, 3JC5’-F = 4 Hz, C5’), 122.5 (C7), 119.6 (CN), 119.5 (C3), 119.2 (d, 4JC6’-F = 3 Hz, C6’), 
115.7 (C4a), 106.4 (C6), 59.7 (Ca), 56.1 (Cc), 48.9 (Cb), 10.6 (Cd), 10.1 (2C, Ce, Ce’); HRMS (ESI) m/z 
calculated for C21H20FN4O2 [M+H]+: 379.1570, found 379.1535. 
 
4.1.2.4. Ethyl 4-[(3-chloro-4-methoxybenzyl)amino]-6-cyano-8-(3-hydroxypropyl)quinoline-
3-carboxylate (15): 
A solution of 0.5 M 9-borabicyclo[3.3.1]nonane (9-BBN) in anhydrous tetrahydrofuran (25 mL, 
12.5 mmol, 6.0 eq.) was slowly added at 0 oC and under argon atmosphere to a solution of allyl 
alcohol (0.86 mL, 12.6 mmol, 6.0 eq.) in anhydrous and previously degassed tetrahydrofuran 
(3.0 mL). The resulting mixture was stirred at rt for 7 hours. This solution was then added, 
under argon atmosphere, to a mixture of 14 [28] (1.0 g, 2.11 mmol, 1.0 eq.), 
tetrakis(triphenylphosphine)palladium(0) (0.24 g, 0.21 mmol, 0.1 eq.), potassium carbonate 
(1.16 g, 8.39 mmol, 4.0 eq.), and water (1.0 mL) in anhydrous N,N-dimethylformamide (40 mL). 
The resulting mixture was stirred at 80 oC for 22 hours. After cooling to room temperature, 
water (40 mL) was added and the aqueous layer was extracted with ethyl acetate (3 × 50 mL). 
The combined organic layers were washed with brine (3 × 100 mL), dried with anhydrous 
magnesium sulfate, filtered and concentrated under reduced pressure. The crude residue was 
purified by column chromatography (SiO2, ethyl acetate/cyclohexane, 5/5, v/v) to give by order 
of elution the desired product 15 (0.25 g, 0.55 mmol, 26%) as a yellow solid, and ethyl 4-[(3-
chloro-4-methoxybenzyl)amino]-6-cyanoquinoline-3-carboxylate (0.24 g, 0.61 mmol, 29%). Rf 
(SiO2, cyclohexane/ethyl acetate, 5/5, v/v): 0.17; Mp: 118 ± 1oC; IR (cm-1)  2231 (νC≡N), 1673 
(νC=O), 1595 (νC=C), 1505 (δN-H), 1262 (νC-O), 1190 (νC-O), 1068 (νC-O); 1H NMR (400 MHz, CDCl3) δ 
9.80 (brt, 1H, NH), 9.18 (s, 1H, H2), 8.40 (d, 1H, 4JH5-H7 = 1.7 Hz, H5), 7.70 (d, 4JH7-H5 = 1.7 Hz, H7), 
7.39 (d, 1H, 4JH2’-H6’ = 2.2 Hz, H2’), 7.26 (dd, 1H, 3JH6’-H5’ = 8.4 Hz, 4JH6’-H2’ = 2.2 Hz, H6’), 6.97 (d, 
1H, 3JH5’-H6’ = 8.4 Hz, H5’), 4.88 (d, 2H, 3JHd-NH = 5.5 Hz, Hd), 4.36 (q, 2H, 3JHb-Hc = 7.1 Hz, Hb), 3.91 
(s, 3H, He), 3.39 (m, 2H, Hh), 3.29 (m, 2H, Hf), 1.94 (m, 2H, Hg), 1.40 (t, 3H, 3JHc-Hb = 7.1 Hz, Hc); 
13C NMR (100 MHz, CDCl3) δ 168.2 (Ca), 156.8 (C4), 155.1 (C4’), 153.0 (C2), 151.5 (C8a), 142.8 
(C8), 132.7 (C7), 130.5 (C5), 130.2 (C1’), 129.4 (C2’), 126.9 (C6’), 123.5 (C3’), 118.8 (CN), 118.6 
22 
 
(C4a), 112.6 (C5’), 107.4 (C6), 104.3 (C3), 61.5 (Cb), 59.5 (Ch), 56.3 (Ce), 52.0 (Cd), 33.9 (Cg), 27.0 
(Cf), 14.3 (Cc); HRMS (ESI) m/z calculated for C24H2535ClN3O4 [M+H]+: 454.1534, found 
C24H2535ClN3O4 [M+H]+: 454.1559 (100%); C24H2537ClN3O4 [M+H]+: 456.1554 (33%). 
 
4.1.2.5. Ethyl 1-[(3-chloro-4-methoxybenzyl)imino]-9-cyano-6,7-dihydro-1H,5H-
pyrido[3,2,1-ij]quinoline-2-carboxylate (17): 
Diethylaminosulfur trifluoride (DAST, 41 µL, 0.31 mmol, 2.0 eq.) was added dropwise, at -60 °C 
and under stirring, to a solution of 15 (70 mg, 0.15 mmol, 1.0 eq.) in anhydrous 
dichloromethane (5.0 mL). The temperature was slowly increased to -30 oC and the mixture 
was stirred between -30 oC and -20 oC for 2 hours before addition of an aqueous saturated 
sodium bicarbonate solution (10 mL) at -20 °C (pH = 7-8). This mixture was extracted with 
dichloromethane (2 × 15 mL). The combined organic layers were washed with brine (50 mL), 
dried over anhydrous magnesium sulfate, filtered and evaporated under reduced pressure. 
The residue was purified by column chromatography (Al2O3, ethyl acetate/cyclohexane, 7/3, 
v/v) to give 17 (30 mg, 84.8 µmol, 57%) as a yellow solid. Rf (SiO2, cyclohexane/ethyl acetate, 
3/7, v/v): 0.25; Mp: 152 ± 1 oC; IR (cm-1)  2224 (νC≡N), 1702 (νC=O), 1574 (νC=N), 1502 (νC=C), 1271 
(νC-O), 1170 (νC-O), 1062 (νC-O); 1H NMR (400 MHz, CDCl3) δ 8.53 (s, 1H, H5), 7.73 (s, 1H, H2), 7.38 
(m, 2H, H2’, H7), 7.29 (dd, 1H, 3JH6’-H5’ = 8.4 Hz, 4JH6’-H2’ = 2.1 Hz, H6’), 6.90 (d, 1H, 3JH5’-H6’ = 8.4 
Hz, H5’), 4.33 (s, 2H, Hd), 4.31 (q, 2H, 3JHb-Hc = 7.1 Hz, Hb), 3.96 (m, 2H, Hh), 3.88 (s, 3H, He), 2.95 
(m, 2H, Hf), 2.14 (m, 2H, Hg), 1.35 (t, 3H, 3JHc-Hb = 7.1 Hz, Hc); 13C NMR (100 MHz, CDCl3) δ 166.3 
(Ca), 153.6 (C4’), 149.2 (C4), 145.4 (C2), 137.5 (C8a), 135.7 (C1’), 131.8 (C7), 129.7 (C5), 129.6 (C2’), 
129.1 (C8), 127.1 (C6’), 126.4 (C4a), 122.2 (C3’), 119.0 (CN), 122.1 (C5’), 107.5 (C6), 106.0 (C3), 
61.1 (Cb), 56.4 (Ce), 55.5 (Cd), 51.7 (Ch), 26.8 (Cf), 20.9 (Cg), 14.5 (Cc); HRMS (ESI) m/z calculated 
for C24H2335ClN3O3 [M+H]+: 436.1428, found C24H2335ClN3O3 [M+H]+: 436.1423 (100%); 
C24H2337ClN3O3 [M+H]+: 438.1433 (33%). 
 
4.1.2.6. Ethyl 8-bromo-4-[(tert-butoxycarbonyl)(3-chloro-4-methoxybenzyl)amino] -6-
cyanoquinoline-3-carboxylate (18): 
Di-tert-butyl dicarbonate (0.92 g, 4.22 mmol, 2.0 eq.), triethylamine (59 µL, 4.22 mmol, 2.0 
eq.) and N,N-4-dimethylaminopyridine (51 mg, 0.42 mmol, 0.2 eq.) were added under argon 
to a solution of 14 [28] (1.0 g, 2.11 mmol, 1.0 eq.) in anhydrous tetrahydrofuran (40 mL). The 
resulting mixture was stirred at rt for 2.5 hours before addition of water (40 mL). The aqueous 
layer was extracted with dichloromethane (3 × 50 mL). The combined organic layers were 
washed with brine (100 mL), dried over magnesium sulfate, filtered and concentrated under 
reduced pressure. The crude residue was purified by column chromatography (SiO2, ethyl 
acetate/cyclohexane, 3/7, v/v) to give the desired product (0.90 g, 1.57 mmol, 74%) as a white 
solid. Rf (SiO2, ethyl acetate/cyclohexane, 3/7, v/v): 0.48; mp: 139 ± 1 oC; IR (cm-1) ν 2234 (νC≡N), 
1708 (νC=O), 1366 (δCH3), 1255 (νC-O), 1151 (νC-O); Analyses of NMR spectra revealed that this 
product was a mixture of two rotamers, named A and B with a ratio A/B = 1/0.3; 1H NMR (400 
MHz, CDCl3) δ 9.41 (s, 1H, H2(B)), 9.40 (s, 1H, H2(A)), 8.03 (d, 1H, 4JH5(A)-H7(A) = 1.7 Hz, H5(A)), 8.02 
(d, 1H, 4JH5(B)-H7(B) = 1.6 Hz, H5(B)), 7.77 (d, 1H, 4JH7(B)-H5(B) = 1.6 Hz, H7(B)), 7.75 (d, 1H, 4JH7(A)-H5(A) 
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= 1.7 Hz, H7(A)), 6.98 (d, 1H, 4JH2’(B)-H6’(B) = 1.9 Hz, H2’(B)), 6.91 (d, 1H, 4JH2’(A)-H6’(A) = 2.0 Hz, H2’(A)), 
6.89 (dd, 1H, 4JH6’(A)-H2’(A) = 2.0 Hz, 3JH6’(A)-H5’(A) = 8.4 Hz, H6’(A)), 6.81 (dd, 1H, 4JH6’(B)-H2’(B) = 1.9 Hz, 
3JH6’(B)-H5’(B) = 8.4 Hz, H6’(B)), 6.67 (m, 1H, H5’(A/B)), 5.00 (d, 1H, 2JHd(A)-Hd’(A) = 14.6 Hz, Hd(A)), 4.89 
(d, 1H, 2JHd(B)-Hd’(B) = 14.9 Hz, Hd(B)), 4.25 (m, 3H, Hb(A/B), Hd’(B)), 4.14 (d, 1H, 2JHd’(A)-Hd(A) = 14.6 Hz, 
Hd’(A)), 3.71 (s, 3H, Hh(B)), 3.69 (s, 3H, Hh(A)), 1.50 (s, 9H, Hg(B)), 1.29 (t, 3H, 3JHc(A/B)-Hb(A/B) = 7.1 Hz, 
Hc(A/B)), 1.08 (s, 9H, Hg(A)); 13C NMR (100 MHz, CDCl3) δ 163.2 (Ca(A)), 162.9 (Ca(B)), 154.8 (C2(A/B)), 
154.6 (C4’(A/B)), 153.5 (C4(B)), 153.0 (C4(A)), 149.4 (Ce(B)), 148.8 (Ce(A)), 148.5 (C8a(B)), 148.4 (C8a(A)), 
134.6 (C5(A/B)), 131.1 (C2’(A/B)), 130.8 (C7(B)), 130.7 (C7(A)), 129.0 (C6’(A/B)), 128.9 (C1’(A/B)), 127.0 
(C4a(B)), 126.9 (C4a(A)), 126.2 (C8(B)), 126.1 (C8(A)), 123.4 (C3(B)), 122.8 (C3(A)), 121.9 (C3’(A/B)), 116.4 
(CN(B)), 116.3 (CN(A)), 111.8 (C5’(A)), 111.7 (C5’(B)), 111.4 (C6(B)), 111.3 (C6(A)), 82.5 (Cf(B)), 81.6 
(Cf(A)), 62.2 (Cb(A)), 62.0 (Cb(B)), 55.8 (Ch(A/B)), 54.3 (Cd(B)), 53.2 (Cd(A)), 28.1 (3C, Cg(B)), 27.7 (3C, 
Cg(A)), 13.8 (Cc(A/B)); HRMS (ESI) m/z calculated for C26H2635Cl79BrN3O5 [M+H]+: 574.0744, found 
C26H2635Cl79BrN3O5 [M+H]+: 574.0799 (77%); C26H2637Cl79BrN3O5 or C26H2635Cl81BrN3O5 [M+H]+: 
576.0721 (100%); C26H2637Cl81BrN3O5 [M+H]+: 578.0730 (24%). 
 
4.1.2.7. Ethyl 4-[(tert-butoxycarbonyl)-(3-chloro-4-methoxybenzyl)amino]-6-cyano-8-(3-
fluoropropyl)quinoline-3-carboxylate (19): 
Tetra-n-butylammonium fluoride (TBAF) solution (1.0 M in THF, 10 mL) was placed into a three-
necked flask under argon atmosphere. The solvent was removed under reduced pressure in 
order to obtain anhydrous and pure TBAF. 3-Bromopropene (1.39 mL, 16.1 mmol, 1.0 eq.) was 
added and the resulting mixture was stirred at room temperature for 30 minutes. The product 
was then collected in a weighed gas trap with an anhydrous argon stream flow as carrier for 
three hours to produce allyl fluoride (310 mg, 5.16 mmol, 32%) as a colorless liquid at -60 oC 
(see Figure S1 in supporting information).  
Under stirring an 0.5 M solution of 9-BBN in tetrahydrofuran (2.1 mL, 1.05 mmol, 2.0 eq.) was 
added at -10 oC to the allyl fluoride solution (10.0 eq.) in anhydrous and previously degassed 
tetrahydrofuran (3 mL). The resulting mixture was stirred at room temperature for 7 hours. 
This solution was added to a mixture of 18 (300 mg, 0.54 mmol, 1.0 eq.), 
tetrakis(triphenylphosphine)palladium(0) (60 mg, 51.9 µmol, 0.1 eq.), potassium carbonate 
(288 mg, 2.08 mmol, 4.0 eq.) and water (0.3 mL) in N,N-dimethylformamide (20 mL). The 
resulting mixture was stirred at 80 oC for 16 hours. After cooling to room temperature, water 
(30 mL) was added and the aqueous layer was extracted with ethyl acetate (3 × 30 mL). The 
combined organic layers were washed with brine (100 mL), dried over anhydrous magnesium 
sulfate, filtered and concentrated under reduced pressure. The crude residue was purified by 
column chromatography (SiO2, ethyl acetate/cyclohexane, 1/9, v/v) to give a mixture of 18 and 
19 which was used in the next step without further purification (200 mg). 
  
4.1.2.8. Tert-butyl 3-chloro-4-methoxybenzyl[6-cyano-8-(3-fluoropropyl)-3- 
(hydroxymethyl)quinolin-4-yl]carbamate (20): 
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A 1.1 M solution of lithium tri-tert-butoxyaluminum hydride in tetrahydrofuran (0.8 mL, 0.88 
mmol) was added to a mixture of crude 19 (100 mg) in anhydrous tetrahydrofuran (5 mL) under 
stirring and argon atmosphere. The resulting mixture was stirred at 60 oC for 20 hours. After 
cooling to room temperature, water (20 mL) was added under stirring. The solution was 
extracted with ethyl acetate (3 × 20 mL) and then with dichloromethane (2 × 20 mL). These 
two organic layers were separately washed with brine (100 mL). The combined organic layers 
were dried over anhydrous magnesium sulfate, filtered and concentrated under reduced 
pressure. The crude residue was purified by column chromatography (SiO2, 
ethanol/dichloromethane, 5/95, v/v) to give the desired product (20 mg, 38.9 µmol) as a white 
solid. Yield: 7%; Rf (SiO2, ethanol/dichloromethane, 5/95, v/v): 0.43; Analyses of NMR spectra 
revealed that this product was a mixture of two rotamers, named A and B with a ratio A/B = 
1/0.7; 1H NMR (400 MHz, CDCl3) δ 9.18 (s, 1H, H2(B)), 9.15 (s, 1H, H2(A)), 8.08 (m, 1H, H5(A)), 7.85 
(m, 1H, H5(B)), 7.75 (m, 1H, H7(A)), 7.72 (m, 1H, H7(B)), 7.13 (m, 1H, H2’(A)), 7.07 (m, 1H, H2’(B)), 
7.04 (m, 1H, H6’(B)), 6.82 (m, 3H, H6’(A), H5’(B), H5’(A)), 5.17 (d, 1H, 2JHe(A)-He’(A) = 14.7 Hz, He(A)), 5.08 
(d, 1H, 2JHe(B)-He’(B) = 14.8 Hz, He(B)), 4.55 (dt, 2H, 3JHi(A)-Hh(A) = 5.6 Hz, 2JHi(A)-F = 47.3 Hz, Hi(A)), 4.36-
4.29 (m, 3H, Hi(B), He(A), He(B)), 4.17 (m, 4H, Ha(A), Ha(B)), 3.90 (s, 3H, Hf(B)), 3.89 (s, 3H, Hf(A)), 3.44 
(m, 4H, Hg(A), Hg(B)), 2.22 (m, 4H, Hh(A), Hh(B)), 1.65 (s, 9H, Hd(A)), 1.26 (s, 9H, Hd(B)); HRMS (ESI) 
m/z calculated for C27H3035ClFN3O4 [M+H]+: 514.1909, found C27H3035ClFN3O4 [M+H]+: 514.1953 
(100%); C27H3037ClFN3O4 [M+H]+: 516.1985 (33%). 
 
4.1.2.9. 4-[(3-Chloro-4-methoxybenzyl)amino]-8-(3-fluoropropyl)-3-
(hydroxymethyl)quinoline-6-carbonitrile (5): 
Trifluoroacetic acid (1.0 mL) was added to a solution of 20 (20 mg, 38.9 µmol, 1.0 eq.) in 
anhydrous dichloromethane (2 mL) under argon atmosphere. The resulting mixture was stirred 
at rt for 3 hours and the solvent was evaporated under reduced pressure. The crude residue 
was purified by column chromatography (SiO2, ethanol/dichloromethane, 5/95, v/v) to give 
the desired product (5.0 mg, 12.1 µmol, 31%) as a white solid; Rf (SiO2, 
ethanol/dichloromethane, 5/95, v/v): 0.19; IR (cm-1)  3412 (νN-H), 2229(νC≡N), 1503 (δN-H), 
1259 (νC-O), 1064 (νC-O), 1020 (νC-F); 1H NMR (400 MHz, CDCl3) δ 8.53 (s, 1H, H2), 8.35 (d, 1H, 
4JH5-H7 = 1.7 Hz, H5), 7.64 (d, 1H, 4JH7-H5 = 1.7 Hz, H7), 7.37 (d, 1H, 4JH2’-H6’ = 2.2 Hz, H2’), 7.21 (dd, 
1H, 4JH6’-H2’ = 2.2 Hz, 3JH6’-H5’ = 8.4 Hz, H6’), 6.94 (d, 1H, 3JH5’-H6’ = 8.4 Hz, H5’), 4.77 (m, 4H, Ha, Hb), 
4.53 (td, 2H, 3JHf-He = 5.9 Hz, 2JHf-F = 47.2 Hz, Hf), 3.92 (s, 3H, Hc), 3.32 (m, 2H, Hd), 2.16 (m, 2H, 
He); HRMS (ESI) m/z calculated for C22H2235ClFN3O2 [M+H]+: 414.1385, found C22H2235ClFN3O2 
[M+H]+: 414.1357 (100%); C22H2237ClFN3O2 [M+H]+: 416.1244 (33%). 
 
4.1.2.10. Ethyl 4-[(3-chloro-4-methoxybenzyl)amino]-6-cyano-8-(4-fluoropiperidin-1-yl) 
quinoline-3-carboxylate (21a): 
4-Fluoropiperidine hydrochloride (133 mg, 0.95 mmol, 3.0 eq.), palladium(II) acetate (7.1 mg, 
31.6 µmol, 0.1 eq.), caesium carbonate (618 mg, 1.90 mmol, 6.0 eq.) and BINAP (39 mg, 62.6 
µmol, 0.2 eq.) were successively added to a solution of 14 [28] (150 mg, 0.32 mmol, 1 eq.) in 
anhydrous toluene (10 mL) in a sealed flask under stirring and argon atmosphere. The resulting 
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mixture was refluxed for 3 hours. After cooling to room temperature, the mixture was filtered 
thought Celite® 545 and washed with dichloromethane (60 mL). The filtrate was concentrated 
under reduced pressure and the crude product was purified by column chromatography (SiO2, 
ethyl acetate/cyclohexane, 4/6, v/v) to give the desired product (90 mg, 0.18 mmol, 56%) as 
a light yellow solid. Rf (SiO2, ethyl acetate/cyclohexane, 4/6, v/v): 0.24; Mp: 110 ± 1 oC; IR (cm-
1)  2226 (νC≡N), 1669 (νC=O), 1502 (δN-H), 1261 (νC-O), 1183 (νC-O), 1027 (νC-F); 1H NMR (400 MHz, 
CDCl3) δ 9.47 (brs, 1H, NH), 9.19 (s, 1H, H2), 8.07 (d, 1H, 4JH5-H7 = 1.2 Hz, H5), 7.38 (d, 1H, 4JH2’-
H6’ = 2.2 Hz, H2’), 7.24 (dd, 1H, 3JH6’-H5’ = 8.4 Hz, 4JH6’-H2’ = 2.2 Hz, H6’), 7.21 (m, 1H, H7), 6.96 (d, 
1H, 3JH5’-H6’ = 8.4 Hz, H5’), 4.93 (m, 1H, Hh), 4.82 (d, 2H, 3JHd-NH = 5.6 Hz, Hd), 4.37 (q, 2H, 3JHb-Hc 
= 7.1 Hz, Hb), 3.91 (s, 3H, He), 3.40 (m, 4H, Hf, Hf’), 2.15 (m, 4H, Hg, Hg’), 1.40 (t, 3H, 3JHc-Hb = 7.1 
Hz, Hc); 13C NMR (100 MHz, CDCl3) δ 168.2 (Ca), 157.0 (C4), 154.9 (C4’), 151.7 (C2), 150.8 (C8), 
147.5 (C8a), 130.7 (C1’), 129.3 (C2’), 126.8 (C6’), 125.0 (C5), 123.1 (C3’), 120.0 (C4a), 119.3 (CN), 
118.1 (C7), 112.5 (C5’), 107.4 (C6), 104.8 (C3), 88.1 (d, 1JCh-F = 170 Hz, Ch), 61.2 (Cb), 56.2 (Ce), 
52.1 (Cd), 47.9 (d, 2C, 3JCf/f’-F = 5 Hz, Cf, Cf’), 31.5 (d, 2C, 2JCg/g’-F = 20 Hz, Cg, Cg’), 14.3 (Cc); HRMS 
(ESI) m/z calculated for C26H2735ClFN4O3 [M+H]+: 497.1756, found C26H2735ClFN4O3 [M+H]+: 
497.1751 (100%); C26H2737ClFN4O3 [M+H]+: 499.1850 (33%). 
 
4.1.2.11. Ethyl 4-[(3-chloro-4-methoxybenzyl)amino]-6-cyano-8-(3-fluoroazetidin-1-
yl)quinoline-3-carboxylate (21b): 
In a sealed flask compound 14 [28] (0.26 g, 0.55 mmol, 1.0 eq.) was diluted in anhydrous 
toluene (20 mL) and 3-fluoroazetidine hydrochloride (91 mg, 0.82 mmol, 1.5 eq.), palladium(II) 
acetate (12 mg, 53.4 µmol, 0.1 eq.), caesium carbonate (0.71 g, 2.18 mmol, 4.0 eq.), and BINAP 
(68 mg, 0.11 mmol, 0.2 eq.) were successively added under argon atmosphere. The resulting 
mixture was stirred at 120 oC for 3 hours. After cooling to room temperature, the mixture was 
filtered on Celite® 545 and washed with ethyl acetate (40 mL). The filtrate was concentrated 
under reduced pressure and the crude residue was purified by column chromatography (SiO2, 
ethyl acetate/cyclohexane, 2/8, v/v) to give the desired product (0.20 g, 0.43 mmol, 78%) as a 
yellow solid. Rf (SiO2, cyclohexane/ethyl acetate, 7/3, v/v): 0.41; Mp: 155 ± 1 oC; IR (cm-1)  
2227 (νC≡N), 1670 (νC=O), 1590 (δN-H), 1504 (νC=C), 1437 (δCH2), 1067 (νC-O), 1180 (νC-O), 1066 (νC-
O), 1024 (νC-F); 1H NMR (400 MHz, CDCl3) δ 9.40 (brs, 1H, NH), 9.02 (s, 1H, H2), 7.79 (d, 1H, 4JH5-
H7 = 1.4 Hz, H5), 7.36 (d, 1H, 4JH2’-H6’ = 2.2 Hz, H2’), 7.23 (dd, 1H, 3JH6’-H5’ = 8.4 Hz, 4JH6’-H2’ = 2.2 
Hz, H6’), 6.94 (d, 1H, 4JH5’-H6’ = 8.4 Hz, H5’), 6.57 (d, 1H, 4JH7-H5 = 1.4 Hz, H7), 5.44 (m, 1H, Hg), 4.79 
(d, 2H, 3JHd-NH = 5.5 Hz, Hd), 4.61 (m, 2H, Hf or Hf’), 4.35 (q, 2H, 3JHb-Hc = 7.1 Hz, Hb), 4.27 (m, 2H, 
Hf or Hf’), 3.90 (s, 3H, He), 1.39 (t, 3H, 3JHc-Hb = 7.1 Hz, Hc); 13C NMR (100 MHz, CDCl3) δ 168.4 
(Ca), 156.3 (C4), 154.9 (C4’), 150.6 (C2), 148.2 (C8), 144.5 (C8a), 130.9 (C1’), 129.4 (C2’), 126.9 (C6’), 
123.1 (C3’), 120.7 (C5), 119.5 (2C, CN, C4a), 112.5 (C5’), 110.9 (C7), 107.7 (C6), 104.9 (C3), 83.4 (d, 
1JCg-F= 201 Hz, Cg), 62.1 (Cf or Cf’), 61.9 (Cf or Cf’), 61.2 (Cb), 56.3 (Ce), 51.9 (Cd), 14.3 (Cc); HRMS 
(ESI) m/z calculated for C24H2335ClFN4O3 [M+H]+: 469.1443, found C24H2335ClFN4O3 [M+H]+: 
469.1453 (100%); C24H2337ClFN4O3 [M+H]+: 471.1489 (33%). 
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4.1.2.12. Ethyl 4-[(3-chloro-4-methoxybenzyl)amino]-6-cyano-8-[((6-fluoro-5-
methoxypyridin-2-yl)methyl)amino]quinoline-3-carboxylate (21c): 
The crude product 10a (2.0 g, synthesis in supporting information) was dissolved in water (20 
mL) before addition of a saturated aqueous sodium bicarbonate solution (20 mL, pH 7/8). This 
aqueous mixture was extracted with dichloromethane (5 × 30 mL). The combined organic 
layers were washed with brine (100 mL), dried over magnesium sulfate, filtered and 
concentrated under reduced pressure. The obtained residue (350 mg) was dissolved in 
anhydrous toluene (3 mL) under argon atmosphere. The resulting solution was added to a 
mixture of 14 [28] (0.30 g, 0.63 mmol, 1.0 eq.), palladium(II) acetate (14 mg, 62.4 µmol, 0.1 
eq.), caesium carbonate (1.03 g, 3.16 mmol, 5.0 eq.) and BINAP (79 mg, 0.13 mmol, 0.2 eq.) in 
anhydrous toluene (10 mL) under argon atmosphere. The resulting mixture was refluxed for 6 
hours. After cooling to room temperature, the mixture was filtered thought a Celite® 545 pad 
and washed with dichloromethane (100 mL). The filtrate was concentrated under reduced 
pressure and the crude product was purified by column chromatography (SiO2, ethyl 
acetate/cyclohexane, 3/7, v/v) to give the desired product (200 mg, 0.36 mmol, 58%) as a 
yellow solid. Rf (SiO2, ethyl acetate/cyclohexane, 3/7, v/v): 0.19; Mp: 175 ± 1oC; IR (cm-1)  
2231 (νC≡N), 1670 (νC=O), 1505 (δN-H), 1265 (νC-O), 1181 (νC-O), 1065 (νC-O), 1022 (νC-F); 1H NMR 
(400 MHz, CDCl3) δ 9.55 (t, 1H, 3JHd-He = 5.2 Hz, Hd), 9.04 (s, 1H, H2), 7.71 (d, 1H, 4JH5-H7 = 1.1 Hz, 
H5), 7.37 (d, 1H, 4JH2’-H6’ = 2.1 Hz, H2’), 7.23 (m, 2H, H6’, H11’), 7.11 (m, 2H, H10’, Hg), 6.94 (d, 1H, 
3JH5’-H6’ = 8.5 Hz, H5’), 6.58 (d, 1H, 4JH7-H5 = 1.1 Hz, H7), 4.84 (d, 2H, 3JHe-Hd = 5.4 Hz, He), 4.47 (d, 
2H, 3JHh-Hg = 5.6 Hz, Hh), 4.35 (q, 2H, 3JHb-Hc = 7.1 Hz, Hb), 3.90 (s, 3H, Hf), 3.88 (s, 3H, Hi), 1.39 (t, 
3H, 3JHc-Hb = 7.1 Hz, Hc); 13C NMR (100 MHz, CDCl3) δ 168.5 (Ca), 156.3 (C4), 154.9 (C4’), 153.2 
(d, 1JC8’-F = 240 Hz, C8’), 151.1 (C2), 145.6 (d, 3JC12’-F = 10 Hz, C12’), 145.1 (C8), 142.0 (2C, C8a, C9’), 
130.8 (C1’), 129.4 (C2’), 126.9 (C6’), 123.1 (C3’), 122.4 (d, 3JC10’-F = 4 Hz, C10’), 119.9 (CN), 118.9 
(d, 4JC11’-F = 4 Hz, C11’), 118.6 (C5), 118.3 (C4a), 112.5 (C5’), 108.1 (C6), 106.7 (C7), 104.9 (C3), 61.3 
(Cb), 56.4 (Ci), 56.3 (Cf), 51.7 (Ce), 47.5 (Ch), 14.3 (Cc); HRMS (ESI) m/z calculated for 
C28H2635ClFN5O4 [M+H]+: 550.1657, found C28H2635ClFN5O4 [M+H]+: 550.1661 (100%); 
C28H2637ClFN5O4 [M+H]+: 552.1703 (33%). 
 
4.1.2.13. Ethyl 4-[(3-chloro-4-methoxybenzyl)amino]-6-cyano-8-[((6-fluoropyridin-2-yl) 
methyl)amino]quinoline-3-carboxylate (21d): 
The crude product 10b (0.14 g, synthesis in supporting information) was dissolved in 
dichloromethane (30 mL) before addition of a saturated aqueous sodium hydrogen carbonate 
solution (50 mL, pH 8-9). After decantation, the aqueous layer was extracted with 
dichloromethane (7 × 30 mL). The combined organic layers were washed with brine (40 mL), 
dried over magnesium sulfate, filtered and concentrated under reduced pressure to obtain (6-
fluoropyridine-2-yl)methylamine (0.13 g, 1.27 mmol, 3.0 eq.) as a yellow oil. This residue was 
dissolved, under argon atmosphere, in a mixture of 14[28] (160 mg, 0.34 mmol, 1.0 eq.), 
palladium(II) acetate (7.6 mg, 33.9 µmol, 0.1 eq.), caesium carbonate (549 mg, 1.69 mmol, 5.0 
eq.), and BINAP (42 mg, 67.5 µmol, 0.2 eq.) in anhydrous toluene (15 mL). The resulting 
mixture was refluxed for 4 hours in a sealed flask. After cooling to room temperature, the 
reaction mixture was filtered on Celite® 545 and washed with dichloromethane (210 mL). The 
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filtrate was concentrated under reduced pressure and the crude residue was purified by 
column chromatography (SiO2, ethyl acetate/cyclohexane, 3/7, v/v) to give the desired 
product 21d (163 mg, 0.31 mmol, 93%) as an orange solid. Rf (SiO2, cyclohexane/ethyl acetate, 
7/3, v/v): 0.38; Mp: 152 ± 1 oC; IR (cm-1)  2229 (νC≡N), 1669 (νC=O), 1594 (δN-H), 1531 (δN-H), 
1501 (νC=C), 1434 (δCH3), 1252 (νC-O), 1191 (νC-O), 1064 (νC-O), 1023 (νC-F); 1H NMR (400 MHz, 
CDCl3) δ 9.61 (brs, 1H, Hd), 9.05 (s, 1H, H2), 7.73 (m, 2H, H5, H10’), 7.38 (d, 1H, 4JH2’-H6’ = 2.2 Hz, 
H2’), 7.23 (m, 3H, H6’, H11’, Hg), 6.94 (d, 1H, 3JH5’-H6’ = 8.5 Hz, H5’), 6.84 (m, 1H, H9’), 6.59 (d, 1H, 
4JH7-H5 = 1.1 Hz, H7), 4.85 (d, 2H, 3JHe-Hd = 5.4 Hz, He), 4.57 (d, 2H, 3JHh-Hg = 6.0 Hz, Hh), 4.36 (q, 
2H, 3JHb-Hc = 7.1 Hz, Hb), 3.90 (s, 3H, Hf), 1.39 (t, 3H, 3JHc-Hb = 7.1 Hz, Hc); 13C NMR (100 MHz, 
CDCl3) δ 168.4 (Ca), 163.5 (d, 1JC8’-F = 239 Hz, C8’), 157.1 (d, 3JC12’-F = 13 Hz, C12’), 156.4 (C4), 155.0 
(C4’), 150.9 (C2), 144.9 (C8), 141.9 (d, 3JC10’-F = 8 Hz, C10’), 141.8 (C8a), 130.6 (C1’), 129.4 (C2’), 
126.9 (C6’), 123.1 (C3’), 119.8 (CN), 118.7 (2C, C5, C3), 118.3 (d, 4JC11’-F = 4 Hz, C11’), 112.6 (C5’), 
108.3 (C6), 108.2 (d, 2JC9’-F = 37 Hz, C9’), 106.9 (C7), 104.9 (C4a), 61.3 (Cb), 56.3 (Cf), 51.7 (Ce), 
48.2 (Ch), 14.3 (Cc); HRMS (ESI) m/z calculated for C27H2435ClFN5O3 [M+H]+: 520.1552, found 
C27H2435ClFN5O3 [M+H]+: 520.1584 (100%); C27H2437ClFN5O3 [M+H]+: 522.1701 (33%). 
 
4.1.2.14. General procedure for 6-9:  
A 1.1 M solution of lithium tri-tert-butoxyaluminum hydride in tetrahydrofuran (0.99 mL, 1.1 
mmol, 6.0 eq. for 6, 7 and 8, 10.0 eq. for 9) was added, under stirring and argon atmosphere, 
to a solution of 21a-d (1.0 eq.) in anhydrous tetrahydrofuran (15 mL). The resulting mixture 
was stirred at 60 oC for 20 hours. After cooling to room temperature, water (20 mL) was added 
under stirring. The aqueous layer was extracted with ethyl acetate (3 x 40 mL), and 
dichloromethane (3 x 30 mL). These two organic layers were separately washed with brine 
(100 mL). The combined organic layers were dried over sodium sulfate, filtered and 
concentrated under reduced pressure. The crude product was purified by column 
chromatography (SiO2, ethanol/dichloromethane, 5/95, v/v) to give the desired products. 
 
4.1.2.14.1. 4-[(3-Chloro-4-methoxybenzyl)amino]-8-(4-fluoropiperidin-1-yl)-3-
(hydroxymethyl)quinoline-6-carbonitrile (6): 
Yellow solid; yield 31% (25 mg, 55.0 µmol); Rf (SiO2, ethanol/dichloromethane, 5/95, v/v): 0.14; 
Mp: 215 ± 1oC; IR (cm-1)  2226 (νC≡N), 1504 (δN-H), 1256 (νC-O), 1064 (νC-O), 1015 (νC-F); 1H NMR 
(400 MHz, DMSO-d6) δ 8.47 (m, 1H, H5), 8.43 (s, 1H, H2), 7.42 (m, 1H, NH), 7.39 (d, 1H, 4JH2’-H6’ 
= 2.1 Hz, H2’), 7.27 (m, 1H, H7), 7.23 (dd, 1H, 3JH6’-H5’ = 8.5 Hz, 4JH6’-H2’ = 2.1 Hz, H6’), 7.10 (d, 1H, 
3JH5’-H6’ = 8.5 Hz, H5’), 5.41 (t, 1H, 3JOH-Ha = 4.9 Hz, OH), 4.88 (m, 1H, Hf), 4.79 (d, 2H, 3JHb-NH = 6.7 
Hz, Hb), 4.44 (d, 2H, 3JHa-OH = 4.9 Hz, Ha), 3.81 (s, 3H, Hc), 3.35 (m, 4H, Hd, Hd’), 2.02 (m, 4H, He, 
He’); 13C NMR (100 MHz, DMSO-d6) δ 153.4 (C4’), 153.1 (C2), 150.4 (C4), 149.8 (C8), 143.9 (C8a), 
134.1 (C1’), 127.8 (C2’), 126.2 (C6’), 122.0 (C5), 121.0 (C3’), 120.7 (C4a), 119.7 (CN), 115.8 (C7), 
115.7 (C3), 112.9 (C5’), 106.6 (C6), 88.5 (d, 1JCf-F = 168 Hz, Cf), 59.6 (Ca), 56.1 (Cc), 47.6 (Cb), 47.5 
(2C, Cd, Cd’), 31.3 (d, 2C, 2JCe/e’-F = 19 Hz, Ce, Ce’); HRMS (ESI) m/z calculated for C24H2535ClFN4O2 
[M+H]+: 455.1650, found C24H2535ClFN4O2 [M+H]+: 455.1617 (100%); C24H2537ClFN4O2 [M+H]+: 
457.1621 (33%). 
28 
 
 
4.1.2.14.2. 4-[(3-Chloro-4-methoxybenzyl)amino]-8-(3-fluoroazetidin-1-yl)-3-
(hydroxymethyl)quinoline-6-carbonitrile (7): 
Yellow solid; yield 55% (90 mg, 0.21 mmol); Rf (SiO2, ethanol/dichloromethane, 5/95, v/v): 
0.47; Mp: 162 ± 1 oC; IR (cm-1)  3396 (νN-H), 2228 (νC≡N), 1503 (δN-H), 1281 (νC-O), 1260 (νC-O), 
1065 (νC-O); 1H NMR (400 MHz, DMSO-d6) δ 8.33 (s, 1H, H2), 8.14 (d, 1H, 4JH5-H7 = 1.4 Hz, H5), 
7.36 (d, 1H, 4JH2’-H6’ = 2.1 Hz, H2’), 7.24 (m, 1H, NH), 7.21 (dd, 1H, 4JH6’-H2’ = 2.1 Hz, 3JH6’-H5’ = 8.4 
Hz, H6’), 7.10 (d, 1H, 3JH5’-H6’ = 8.4 Hz, H5’), 6.69 (d, 1H, 4JH7-H5 = 1.4 Hz, H7), 5.47 (m, 1H, He), 5.36 
(t, 1H, 3JOH-Ha = 5.2 Hz, OH), 4.76 (d, 2H, 3JHb-NH = 6.7 Hz, Hb), 4.54 (m, 2H, Hd or Hd’), 4.41 (d, 2H, 
3JHa-OH = 5.2 Hz, Ha), 4.25 (m, 2H, Hd or Hd’), 3.81 (s, 3H, Hc); 13C NMR (100 MHz, DMSO-d6) δ 
153.4 (C4’), 152.8 (C2), 149.4 (C4), 147.8 (C8), 141.6 (C8a), 134.3 (C1’), 127.8 (C2’), 126.1 (C6’), 
121.0 (C3’), 120.4 (C4a), 119.9 (CN), 117.2 (C5), 115.9 (C3), 112.9 (C5’), 108.1 (C7), 106.9 (C6), 84.3 
(d, 1JCe-F = 196 Hz, Ce), 61.7 (d, 2C, 2JCd/d’-F = 5 Hz, Cd/d’), 59.7 (Ca), 56.0 (Cc), 47.5 (Cb); HRMS (ESI) 
m/z calculated for C22H2135ClFN4O2 [M+H]+: 427.1337, found C22H2135ClFN4O2 [M+H]+: 427.1350 
(100%); C22H2137ClFN4O2 [M+H]+: 429.1253 (33%). 
 
4.1.2.14.3. 4-[(3-chloro-4-methoxybenzyl)amino]-8-[((6-fluoro-5-methoxypyridin-2-
yl)methyl)amino]-3-(hydroxymethyl)quinoline-6-carbonitrile (8): 
Light yellow solid; yield 55% (80 mg, 0.16 mmol); Rf (SiO2, ethanol/dichloromethane, 5/95, 
v/v): 0.40;  Mp: 194 ± 1 oC; IR (cm-1)  3409 (νN-H), 2227 (νC≡N), 1546 (δN-H), 1260 (νC-O), 1004 (νC-
F); 1H NMR (400 MHz, DMSO-d6) δ 8.38 (s, 1H, H2), 8.01 (d, 1H, 4JH5-H7 = 1.2 Hz, H5), 7.59 (dd, 
1H, 4JH10’-F = 10.6 Hz, 3JH10’-H11’ = 8.2 Hz, H10’), 7.45 (t, 1H, 3JHe-Hf = 6.3 Hz, He), 7.37 (d, 1H, 4JH2’-
H6’ = 2.1 Hz, H2’), 7.33 (t, 1H, 3JHb-Hc = 6.8 Hz, Hb), 7.25 (d, 1H, 3JH11’-H10’ = 8.2 Hz, H11’), 7.21 (dd, 
1H, 3JH6’-H5’ = 8.5 Hz, 4JH6’-H2’ = 2.1 Hz, H6’), 7.10 (d, 1H, 3JH5’-H6’ = 8.5 Hz, H5’), 6.65 (d, 1H, 4JH7-H5 
= 1.2 Hz, H7), 5.39 (t, 1H, 3JOH-Ha = 5.1 Hz, OH), 4.79 (d, 2H, 3JHc-Hb = 6.8 Hz, Hc), 4.49 (d, 2H, 3JHf-
He = 6.3 Hz, Hf), 4.44 (d, 2H, 3JHa-OH = 5.1 Hz, Ha), 3.84 (s, 3H, Hg), 3.81 (s, 3H, Hd); 13C NMR (100 
MHz, DMSO-d6) δ 153.4 (C4’), 152.8 (C2), 151.9 (d, 1JC8’-F = 235 Hz, C8’), 149.9 (C4), 146.1 (d, 
3JC12’-F = 11 Hz, C12’), 145.0 (C3), 140.8 (d, 2JC9’-F = 15 Hz, C9’), 139.3 (C8a), 134.3 (C1’), 127.7 (C2’), 
126.1 (C6’), 123.5 (d, 3JC10’-F = 3 Hz, C10’), 121.0 (C3’), 120.3 (CN), 119.7 (d, 4JC11’-F = 3 Hz, C11’), 
119.2 (C4a), 116.1 (C3), 114.8 (C5), 112.9 (C5’), 107.2 (C6), 103.6 (C7), 59.7 (Ca), 56.1 (Cg), 56.0 
(Cd), 47.3 (Cc), 46.2 (Cf); HRMS (ESI) m/z calculated for C26H2435ClFN5O3 [M+H]+: 508.1552, 
found C26H2435ClFN5O3 [M+H]+: 508.1528 (100%); C26H2437ClFN5O3 [M+H]+: 510.1570 (33%). 
 
4.1.2.14.4. 4-[(3-Chloro-4-methoxybenzyl)amino]-8-[((6-fluoropyridin-2-yl)methyl)amino]-
3-(hydroxymethyl)quinoline-6-carbonitrile (9):  
Light yellow solid; yield 41% (15 mg, 31.4 µmol); Rf (SiO2, ethanol/dichloromethane, 1/9, v/v): 
0.40; Mp: 186 ± 1 oC; IR (cm-1)  3400 (νN-H), 2232 (νC≡N), 1550 (δN-H), 1504 (δN-H), 1436 (δCH3), 
1261 (νC-O), 1228 (νC-O); 1H NMR (400 MHz, DMSO-d6) δ 8.40 (s, 1H, H2), 8.03 (m, 1H, H5), 7.93 
(m, 1H, H10’), 7.55 (t, 1H, 3JHe-Hf = 6.2 Hz, He), 7.38 (d, 1H, 4JH2’-H6’ = 2.1 Hz, H2’), 7.35 (t, 1H, 3JHb-
Hc = 6.7 Hz, Hb), 7.29 (m, 1H, H11’), 7.23 (dd, 1H, 3JH6’-H5’ = 8.6 Hz, 4JH6’-H2’ = 2.1 Hz, H6’), 7.10 (d, 
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1H, 3JH5’-H6’ = 8.6 Hz, H5’), 7.05 (m, 1H, H9’), 6.66 (d, 1H, 4JH7-H5 = 1.2 Hz, H7), 5.40 (brs, 1H, OH), 
4.80 (d, 2H, 3JHc-Hb = 6.7 Hz, Hc), 4.59 (d, 2H, 3JHf-He = 6.2 Hz, Hf), 4.45 (d, 2H, 3JHa-OH = 3.7 Hz, Ha), 
3.81 (s, 3H, Hd); 13C NMR (100 MHz, DMSO-d6) δ 162.6 (d, 1JC8’-F = 235 Hz, C8’), 158.0 (d, 3JC12’-F 
= 13 Hz, C12’), 153.4 (C4’), 152.8 (C2), 150.0 (C4), 145.0 (C8), 142.7 (d, 3JC10’-F = 8 Hz, C10’), 139.3 
(C8a), 134.3 (C1’), 127.8 (C2’), 126.1 (C6’), 121.0 (C3’), 120.2 (CN), 119.2 (C4a), 118.9 (d, 4JC11’-F = 3 
Hz, C11’), 116.1 (C3), 115.0 (C5), 112.9 (C5’), 107.6 (d, 2JC9’-F = 37 Hz, C9’), 107.3 (C6), 103.7 (C7), 
59.8 (Ca), 56.0 (Cd), 47.4 (Cc), 46.9 (Cf); HRMS (ESI) m/z calculated for C25H2235ClFN5O2 [M+H]+: 
478.1446, found C25H2235ClFN5O2 [M+H]+: 478.1437 (100%); C25H2237ClFN5O2 [M+H]+: 480.1476 
(33%). 
 
4.1.2.15. Preparation of precursors for radiolabelling 
4.1.2.15.1. 8-Bromo-4-[(3-chloro-4-methoxybenzyl)amino]-3-(hydroxymethyl)quinoline-6-
carbonitrile (22): 
A 1.1 M solution of lithium tri-tert-butoxyaluminum hydride in tetrahydrofuran (5.70 mL, 6.27 
mmol, 6.0 eq.) was added, under stirring and argon atmosphere, to a solution of 14 [28] (0.5 
g, 1.05 mmol, 1.0 eq.) in anhydrous tetrahydrofuran (30 mL). The resulting mixture was stirred 
at 60 oC for 20 hours. After cooling to room temperature, water (20 mL) was added under 
stirring. The aqueous layer was extracted with ethyl acetate (3 × 30 mL) and dichloromethane 
(3 × 30 mL). These two organic layers were separately washed with brine (100 mL), then 
combined, dried over magnesium sulfate, filtered and concentrated under reduced pressure. 
The crude residue was purified by column chromatography (SiO2, ethanol/dichloromethane, 
5/95, v/v) to give the desired product 22 (0.31 g, 0.72 mmol, 69%) as a white solid. Rf (SiO2, 
ethanol/dichloromethane, 5/95, v/v): 0.41; Mp: 209 ± 1 oC; IR (cm-1)  3403 (νN-H), 2229 (νC≡N), 
1505 (δN-H), 1261 (νC-O), 1015 (νC-O); 1H NMR (400 MHz, DMSO-d6) δ 8.96 (d, 1H, 4JH5-H7 = 1.5 
Hz, H5), 8.53 (s, 1H, H2), 8.35 (d, 1H, 4JH7-H5 = 1.5 Hz, H7), 7.67 (t, 1H, 3JNH-Hb = 6.7 Hz, NH), 7.40 
(d, 1H, 4JH2’-H6’ = 2.1 Hz, H2’), 7.24 (dd, 1H, 4JH6’-H2’ = 2.1 Hz, 3JH6’-H5’ = 8.5 Hz, H6’), 7.10 (d, 1H, 
3JH5’-H6’ = 8.5 Hz, H5’), 5.48 (t, 1H, 3JOH-Ha = 5.2 Hz, OH), 4.85 (d, 2H, 3JHb-NH = 6.7 Hz, Hb), 4.46 (d, 
2H, 3JHa-OH = 5.2 Hz, Ha), 3.81 (s, 3H, Hc); 13C NMR (100 MHz, DMSO-d6) δ 156.7 (C2), 153.5 (C4’), 
150.3 (C4), 146.8 (C8a), 133.8 (C1’), 132.6 (C7), 129.7 (C5), 127.9 (C2’), 126.2 (C6’), 125.5 (C8), 
121.1 (C3’), 120.4 (C4a), 118.1 (CN), 116.2 (C3), 113.0 (C5’), 106.7 (C6), 59.6 (Ca), 56.1 (Cc), 47.5 
(Cb); HRMS (ESI) m/z calculated for C19H1635Cl79BrN3O2 [M+H]+: 432.0114, found 
C19H1635Cl79BrN3O2 [M+H]+: 432.0105 (77%); C19H1637Cl79BrN3O2 [M+H]+: 434.0087 (100%); 
C19H1637Cl81BrN3O2 [M+H]+: 436.0092 (24%). 
 
4.1.2.15.2. 8-Bromo-4-[(3-chloro-4-methoxybenzyl)amino]-3-
[((triisopropylsilyl)oxy)methyl]quinoline-6-carbonitrile (23): 
Triisopropylsilyl chloride (74 µL, 0.35 mmol, 1.5 eq.), triethylamine (64 µL, 0.46 mmol, 2.0 eq.), 
N,N-4-dimethylaminopyridine (5.6 mg, 45.8 µmol, 0.2 eq.) were added, under argon 
atmosphere and stirring, to a solution of 22 (0.10 g, 0.25 mmol, 1.0 eq.) in anhydrous N,N-
dimethylformamide (10 mL). The resulting mixture was stirred at room temperature for 36 
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hours before addition of water (20 mL). The solution was extracted with ethyl acetate (3 × 30 
mL) and the combined organic layers were washed with brine (3 × 50 mL), dried over 
anhydrous magnesium sulfate, filtered, and then concentrated under reduced pressure. The 
crude residue was purified by column chromatography (SiO2, gradient: cyclohexane to ethyl 
acetate/cyclohexane, 2/8, v/v) to give the desired product 23 (0.11 g, 0.19 mmol, 76%) as a 
white solid. Rf (SiO2, ethyl acetate/cyclohexane, 2/8, v/v): 0.33; Mp: 124 ± 1 oC; IR (cm-1)  3281 
(νN-H), 2943 (νas CH3), 2864 (νs CH3), 2227 (νC≡N), 1503 (δN-H), 1256 (νC-O), 1060 (νC-O), 807 (νC-Si); 1H 
NMR (200 MHz, CDCl3) δ 8.57 (s, 1H, H2), 8.56 (s, 1H, H5), 8.04 (s, 1H, H7), 7.35 (d, 1H, 4JH2’-H6’ 
= 1.8 Hz, H2’), 7.17 (dd, 1H, 3JH6’-H5’ = 8.3 Hz , 4JH6’-H2’ = 1.8 Hz, H6’), 6.90 (d, 1H, 3JH5’-H6’ = 8.3 Hz, 
H5’), 6.59 (brs, 1H, NH), 4.81 (s, 2H, Ha), 4.77 (d, 2H, 3JHd-NH = 5.2 Hz, Hd), 3.89 (s, 3H, He), 1.06 
(m, 3H, Hb), 0.98 (s, 18H, Hc); 13C NMR (50 MHz, CDCl3) δ 155.1 (C4’), 153.5 (C4), 152.0 (C2), 
147.9 (C8a), 133.1 (C7), 131.5 (C1’), 130.7 (C5), 129.4 (C2’), 127.0 (C6’), 125.8 (C8), 123.3 (C3’), 
120.7 (C4a), 119.1 (C3), 117.9 (CN), 112.5 (C5’), 107.7 (C6), 63.2 (Ca), 56.3 (Ce), 52.1 (Cd), 17.9 
(6C, Cc), 11.8 (3C, Cb); HRMS (ESI) m/z calculated for C28H3679Br35ClN3O2Si [M+H]+: 588.1449, 
found C28H3679Br35ClN3O2Si [M+H]+: 588.1412 (77%); C28H3679Br37ClN3O2Si [M+H]+: 590.1365 
(100%); C28H3681Br37ClN3O2Si [M+H]+: 592.1424 (24%). 
 
4.1.2.15.3. 4-[(3-Chloro-4-methoxybenzyl)amino]-8-(3-hydroxyazetidin-1-yl)-3-
[((triisopropylsilyl)oxy)methyl]quinoline-6-carbonitrile (24): 
A solution of tert-butyl 3-hydroxyazetidine-1-carboxylate (0.60 g, 3.46 mmol, 3.4 eq.) in 
anhydrous chloromethane (5.0 mL) was placed in a flask equipped with a screw cap and 
trifluoroacetic acid (2.5 mL) was added under argon atmosphere. The resulting mixture was 
stirred at room temperature for one hour and afterwards evaporated under vacuum for 3 
hours. The residue was dissolved in anhydrous toluene (20 mL) under argon atmosphere and 
caesium carbonate (2.00 g, 6.14 mmol, 6.0 eq.) was added. After stirring at room temperature 
for 15 minutes, 23 (0.60 g, 1.02 mmol, 1.0 eq.), palladium(II) acetate (46 mg, 0.20 mmol, 0.2 
eq.), and 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (BINAP) (127 mg, 0.20 mmol, 0.2 eq.) 
were added. The resulting mixture was refluxed for 3 hours. After cooling to room 
temperature, the reaction mixture was concentrated under reduced pressure and the crude 
residue was purified by column chromatography (SiO2, ethyl acetate/cyclohexane, 5/5, v/v) to 
give the desired product 24 (0.30 g, 0.52 mmol, 51%) as an orange solid. Rf (SiO2, 
cyclohexane/ethyl acetate, 5/5, v/v): 0.29; Mp: 105 ± 1 oC; IR (cm-1)  2943 (νas CH3), 2865 (νs 
CH3), 2222 (νC≡N), 1502 (δN-H), 1436 (δCH3), 1257 (νC-O), 1064 (νC-O), 809 (νC-Si), 683 (νC-Cl); 1H NMR 
(200 MHz, CDCl3) δ 8.35 (s, 1H, H2), 7.80 (d, 1H, 4JH5-H7 = 1.4 Hz, H5), 7.34 (d, 1H, 4JH2’-H6’ = 2.1 
Hz, H2’), 7.16 (dd, 1H, 3JH6’-H5’ = 8.4 Hz, 4JH6’-H2’ = 2.1 Hz, H6’), 6.89 (d, 1H, 3JH5’-H6’ = 8.4 Hz, H5’), 
6.54 (d, 1H, 4JH7-H5 = 1.5 Hz, H7), 6.07 (brs, 1H, NH), 4.76 (m, 3H, Ha, Hg), 4.67 (d, 2H, 3JHd-NH = 
5.7 Hz, Hd), 4.57 (m, 2H, Hf), 4.03 (m, 2H, Hf’), 3.90 (s, 3H, He), 1.00 (m, 21H, Hb, Hc); 13C NMR 
(50 MHz, CDCl3) δ 154.9 (C4’), 153.0 (C4), 148.8 (C8), 148.6 (C2), 143.0 (C8a), 132.4 (C1’), 129.6 
(C2’), 127.1 (C6’), 123.0 (C3’), 121.1 (C4a), 120.0 (2C, CN, C3), 119.3 (C5), 112.4 (C5’), 109.2 (C7), 
108.0 (C6), 64.3 (2C, Cf, Cf’), 63.4 (Cg), 63.2 (Ca), 56.4 (Ce), 52.2 (Cd), 18.0 (6C, Cc), 11.9 (3C, Cb); 
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HRMS (ESI) m/z calculated for C31H4235ClN4O3Si [M+H]+: 581.2709, found C31H4235ClN4O3Si 
[M+H]+: 581.2711 (100%); C31H4237ClN4O3Si [M+H]+: 583.2685 (33%). 
 
4.1.2.15.4 General procedure for 25 & 26:  
4-Nitrobenzenesulfonyl chloride (3.0 eq.), triethylamine (0.29 mL, 2.08 mmol, 5.0 eq.), and 
DMAP (0.2 eq.) were added, under stirring and argon atmosphere, to a solution of 24 (1.0 eq.) 
in anhydrous dichloromethane (20 mL). The resulting mixture was stirred at room temperature 
for 19 hours before addition of water (60 mL). This mixture was extracted with ethyl acetate 
(3 x 60 mL). The combined organic layers were washed with brine (100 mL), dried over 
magnesium sulfate, filtered and concentrated under reduced pressure at room temperature. 
The crude residue was purified by column chromatography (SiO2, ethyl acetate/cyclohexane, 
2/8, v/v) to give the desired products. 
4.1.2.15.4.1. 1-[4-((3-Chloro-4-methoxybenzyl)amino)-6-cyano-3-
(((triisopropylsilyl)oxy)methyl)quinolin-8-yl]azetidin-3-yl-4-methylbenzenesulfonate (25):  
Yellow solid; yield 72% (0.22 g, 0.30 mmol); Rf (SiO2, ethyl acetate / cyclohexane, 5 / 5, v / v): 
0.73; Mp: 67 ± 1 oC; IR (cm-1)  2942 (νas CH3), 2864 (νs CH3), 2224 (νC≡N), 1502 (δN-H), 1437 (νas 
SO2), 1176 (νs SO2), 1063 (νC-O), 812 (νC-Si); 1H NMR (200 MHz, CDCl3) δ 8.31 (s, 1H, H2), 7.82 (m, 
3H, H5, H8’), 7.38 (m, 2H, H9’), 7.33 (d, 1H, 4JH2’-H6’ = 2.2 Hz, H2’), 7.15 (dd, 1H, 3JH6’-H5’ = 8.4 Hz, 
4JH6’-H2’ = 2.2 Hz, H6’), 6.89 (d, 1H, 3JH5’-H6’ = 8.4 Hz, H5’), 6.46 (s, 1H, H7), 5.96 (brs, 1H, NH), 5.22 
(m, 1H, Hg), 4.74 (s, 2H, Ha), 4.63 (m, 4H, Hd, Hf), 4.16 (m, 2H, Hf’), 3.90 (s, 3H, He), 2.48 (s, 3H, 
Hh), 1.16 (m, 21H, Hb, Hc); 13C NMR (50 MHz, CDCl3) δ 154.9 (C4’), 152.9 (C4), 148.6 (C2), 147.9 
(C8), 145.5 (C10’), 142.8 (C8a), 133.1 (C7’), 132.2 (C1’), 130.2 (2C, C9’), 129.5 (C2’), 128.0 (2C, C8’), 
127.1 (C6’), 123.1 (2C, C3’, C4a), 120.1 (C5), 119.8 (CN), 119.2 (C3), 112.4 (C5’), 108.9 (C7), 107.9 
(C6), 69.3 (Cg), 63.1 (Ca), 61.2 (2C, Cf, Cf’), 56.3 (Ce), 52.1 (Cd), 21.8 (Ch), 17.9 (6C, Cc), 11.8 (3C, 
Cb); HRMS (ESI) m/z calculated for C38H4835ClN4O5SSi [M+H]+: 735.2798, found 
C38H4835ClN4O5SSi [M+H]+: 735.2798 (100%); C38H4837ClN4O5SSi [M+H]+: 737.2780 (33%). 
4.1.2.15.4.2. 1-[4-((3-Chloro-4-methoxybenzyl)amino)-6-cyano-3-
(((triisopropylsilyl)oxy)methyl)quinolin-8-yl]azetidin-3-yl-4-nitrobenzenesulfonate (26):  
Yellow solid; yield 78% (0.30 g, 0.39 mmol); Rf (SiO2, ethyl acetate/cyclohexane, 3/7, v/v): 0.44; 
Mp: 65 ± 1 oC; IR (cm-1)  2970 (νas CH3), 2901 (νs CH3), 2232 (νC≡N), 1259 (νC-O), 1187 (νC-O), 1066 
(νC-O), 810 (νC-Si); 1H NMR (200 MHz, CDCl3) δ 8.42 (m, 2H, H9’), 8.29 (s, 1H, H2), 8.14 (m, 2H, 
H8’), 7.83 (d, 1H, 4JH5-H7 = 1.3 Hz, H5), 7.32 (d, 1H, 4JH2’-H6’ = 2.2 Hz, H2’), 7.15 (dd, 1H, 3JH6’-H5’ = 
8.4 Hz, 4JH6’-H2’ = 2.2 Hz, H6’), 6.88 (d, 1H, 3JH5’-H6’ = 8.4 Hz, H5’), 6.47 (d, 1H, 4JH7-H5 = 1.3 Hz, H7), 
5.96 (brs, 1H, NH), 5.31 (m, 1H, Hg), 4.73 (s, 2H, Ha), 4.65 (m, 4H, Hd, Hf), 4.24 (m, 2H, Hf’), 3.88 
(s, 3H, He), 0.99 (m, 21H, Hb, Hc); 13C NMR (50 MHz, CDCl3) δ 154.8 (C4’), 152.7 (C4), 151.0 (C10’), 
149.1 (C2), 147.6 (C8), 143.0 (C8a), 141.9 (C7’), 132.2 (C1’), 129.4 (C2’), 129.3 (2C, C9’), 127.0 (C6’), 
124.7 (2C, C8’), 123.0 (C3’), 121.0 (C4a), 120.3 (C5), 119.7 (CN), 119.2 (C3), 112.4 (C5’), 108.8 (C7), 
107.7 (C6), 70.7 (Cg), 63.1 (Ca), 61.1 (2C, Cf, Cf’), 56.3 (Ce), 52.0 (Cd), 17.9 (6C, Cc), 11.8 (3C, Cb); 
HRMS (ESI) m/z calculated for C37H4535ClN5O7SSi [M+H]+: 766.2492, found C37H4535ClN5O7SSi 
[M+H]+: 766.2492 (100%); C37H4537ClN5O7SSi  [M+H]+: 768.2475 (33%). 
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4.1.2.15.5. General procedure for 27 & 28:  
A 1.0 M solution of tetra-n-butylammonium fluoride in tetrahydrofuran (0.39 mL, 0.39 mmol, 
1.0 eq.) was added slowly at 0 °C, under stirring and argon atmosphere, to a solution of 25 or 
26 (1.0 eq.) in anhydrous THF (20 mL). The resulting mixture was stirred at room temperature 
for 30 minutes before addition of water at 0 °C. The resulting solution was extracted with ethyl 
acetate (3 x 50 mL) and the combined organic layers were washed with brine (100 mL), dried 
over magnesium sulfate, filtered and concentrated under reduced pressure at room 
temperature. The crude residue was purified by column chromatography (SiO2, ethyl 
acetate/cyclohexane, 5/5, v/v) to give the desired product. 
4.1.2.15.5.1. 1-[4-((3-Chloro-4-methoxybenzyl)amino)-6-cyano-3-(hydroxymethyl)quinolin-
8-yl]azetidin-3-yl-4-methylbenzenesulfonate (27):  
Light yellow solid; yield 70% (0.12 g, 0.21 mmol); Rf (SiO2, methanol/dichloromethane, 3/7, 
v/v): 0.39; Mp: 155 ± 1 oC; IR (cm-1)  2226 (νC≡N), 1502 (δN-H), 1349 (νas SO2), 1173 (νs SO2), 1064 
(νC-O), 812 (νC-Cl); 1H NMR (200 MHz, CDCl3) δ 8.33 (s, 1H, H2), 7.83 (d, 2H, 3JH8’-H9’ = 8.4 Hz, H8’), 
7.74 (d, 1H, 4JH5-H7 = 1.3 Hz, H5), 7.39 (d, 2H, 3JH9’-H8’ = 8.4 Hz, H9’), 7.32 (d, 1H, 4JH2’-H6’ = 2.2 Hz, 
H2’), 7.16 (dd, 1H, 3JH6’-H5’ = 8.4 Hz, 4JH6’-H2’ = 2.2 Hz, H6’), 6.91 (d, 1H, 3JH5’-H6’ = 8.4 Hz, H5’), 6.48 
(d, 1H, 4JH7-H5 = 1.3 Hz, H7), 5.84 (brs, 1H, NH), 5.22 (m, 1H, Hg), 4.68 (s, 4H, Ha, Hb), 4.59 (m, 
2H, Hd), 4.14 (m, 2H, Hd’), 3.90 (s, 3H, Hc), 2.49 (s, 3H, Hh); 13C NMR (50 MHz, CDCl3) δ 154.8 
(C4’), 152.4 (C4), 149.8 (C2), 147.8 (C8), 145.6 (C10’), 142.5 (C8a), 133.1 (C7’), 132.1 (C1’), 130.2 
(2C, C9’), 129.4 (C2’), 128.1 (2C, C8’), 126.9 (C6’), 122.9 (C3’), 120.9 (C4a), 119.7 (CN), 119.3 (C5), 
118.5 (C3), 112.5 (C5’), 109.2 (C7), 108.1 (C6), 69.3 (Ce), 61.9 (Ca), 61.3 (2C, Cd, Cd’), 56.3 (Cc), 
51.8 (Cb), 21.9 (Cf); HRMS (ESI) m/z calculated for C29H2835ClN4O5S [M+H]+: 579.1463, found 
C29H2835ClN4O5S [M+H]+: 579.1473 (100%); C29H2837ClN4O5S [M+H]+: 581.1436 (33%). 
4.1.2.15.5.2. 1-[4-((3-Chloro-4-methoxybenzyl)amino)-6-cyano-3-(hydroxymethyl)quinolin-
8-yl]azetidin-3-yl-4-nitrobenzenesulfonate (28):  
Light yellow solid; yield 64% (0.15 g, 0.25 mmol); Rf (SiO2, methanol/dichloromethane, 5/5, 
v/v): 0.21; Mp: 128 ± 1 oC; IR (cm-1)  2226 (νC≡N), 1502 (δNH), 1347 (νas SO2), 1187 (νs SO2), 1063 
(νC-O), 1014 (νC-O); 1H NMR (200 MHz, CDCl3) δ 8.42 (d, 2H, 3JH9’-H8’ = 8.4 Hz, H9’), 8.28 (s, 1H, 
H2), 8.14 (d, 1H, 3JH8’-H9’ = 8.4 Hz, H8’), 7.72 (s, 1H, H5), 7.30 (d, 1H, 4JH2’-H6’ = 2.1 Hz, H2’), 7.15 
(dd, 1H, 3JH6’-H5’ = 8.5 Hz, 4JH6’-H2’ = 2.1 Hz, H6’), 6.89 (d, 1H, 3JH5’-H6’ = 8.5 Hz, H5’), 6.46 (s, 1H, H7), 
5.81 (se, 1H, NH), 5.30 (m, 1H, Hg), 4.66 (m, 4H, Ha, Hb), 4.59 (m, 2H, Hd), 4.20 (m, 2H, Hd’), 3.89 
(s, 3H, Hc); 13C NMR (50 MHz, CDCl3) δ 154.9 (C4’), 152.5 (C4), 151.1 (C10’), 149.9 (C2), 147.4 (C8), 
142.3 (C8a), 141.8 (C7’), 132.0 (C1’), 129.4 (2C, C8’), 129.3 (C2’), 126.9 (C6’), 124.8 (2C, C9’), 123.0 
(C3’), 120.8 (C4a), 119.7 (C5), 119.6 (CN), 118.4 (C3), 112.5 (C5’), 109.5 (C7), 108.1 (C6), 70.7 (Ce), 
61.9 (Ca), 61.2 (2C, Cd, Cd’), 56.4 (Cc), 51.8 (Cb); HRMS (ESI) m/z calculated for C28H2535ClN5O7S 
[M+H]+: 610.1158, found C28H2535ClN5O7S [M+H]+: 610.1161 (100%); C28H2537ClN5O7S [M+H]+: 
612.1132 (33%). 
 
4.2 Radiochemistry 
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4.2.1. General 
No-carrier-added [18F]fluoride was produced via the [18O(p,n)18F] nuclear reaction by 
irradiation of an [18O]H2O target (Hyox 18 enriched water, Rotem Industries Ltd, Israel) on a 
Cyclone 18/9 (iba RadioPharma Solutions, Belgium) with fixed energy proton beam using Nirta 
[18F]fluoride XL target.  
Radio thin layer chromatography (radio-TLC) was performed on silica gel (Polygram® SIL 
G/UV254) pre-coated plates with a mixture of ethyl acetate/n-hexane 4/1 (v/v) as eluent. The 
plates were exposed to storage phosphor screens (BAS-IP MS 2025, FUJIFILM Co., Tokyo, 
Japan) and recorded using the Amersham Typhoon RGB Biomolecular Imager (GE Healthcare 
Life Sciences). Images were quantified with the ImageQuant TL8.1 software (GE Healthcare 
Life Sciences).  
Analytical chromatographic separations were performed on a JASCO LC-2000 system, 
incorporating a PU-2080Plus pump, AS-2055Plus auto injector (100 L sample loop), and a UV-
2070Plus detector coupled with a gamma radioactivity HPLC detector (Gabi Star, raytest 
Isotopenmessgeräte GmbH). Data analysis was performed with the Galaxie chromatography 
software (Agilent Technologies) using the chromatograms obtained at 254 nm. A Reprosil-Pur 
C18-AQ column (250 x 4.6 mm; 5 µm; Dr. Maisch HPLC GmbH; Germany) with ACN/20 mM 
NH4OAc aq. (pH 6.8) as eluent mixture and a flow of 1.0 mL/min was used (gradient: eluent A 
10% ACN/20 mM NH4OAc aq.; eluent B 90% ACN/20 mM NH4OAc aq.; 0–10 min 100% A, 10–
30 min up to 100% B, 30–35 min 100% B , 35–37 min up to 100% A, 37–45 min 100% A). 
The ammonium acetate and sodium dodecyl sulfate (SDS) concentrations stated as 20 mM 
NH4OAc aq. and 100 mM aq., respectively, correspond to the concentration in the aqueous 
component of an eluent mixture.  
The molar activities were determined on the basis of a calibration curve carried out under 
isocratic HPLC conditions (50% ACN/20 mM NH4OAcaq; Reprosil-Pur C18-AQ, 250 x 4.6 mm) 
using chromatograms obtained at 254 nm. 
 
4.2.2. Radiosyntheses 
4.2.2.1. Manual syntheses with tosylate 27 as precursor 
No carrier added [18F]fluoride in 1.5 mL of water was trapped on a Chromafix® 30 PS-HCO3- 
cartridge (ABX, Radeberg, Germany). The activity was eluted with 300 µL of an aqueous 
solution of potassium carbonate (K2CO3, 1.8 mg, 13 µmol) into a 4 mL V-vial and Kryptofix 2.2.2 
(K2.2.2, 11 mg, 29 µmol) in 1 mL of ACN was added. The aqueous [18F]fluoride was azeotropically 
dried under vacuum and nitrogen flow within 7-10 min using a single mode microwave (75 W, 
at 50  ̶ 60 °C, power cycling mode; Discover PETWave from CEM corporation, USA). Two 
aliquots of ACN (2 x 1.0 mL) were added during the drying procedure and the final complex 
was dissolved in 1.0 mL of labeling solvent and divided in two portions. Accordingly, most of 
the labeling reactions were performed with half of the K[18F]F/K222 complex. Thereafter, a 
solution of 2.0 - 2.5 mg of precursor 27 in 500 µL of the appropriate solvent was added, and 
18F-labeling was performed at different temperatures in dependence of the solvent used (90, 
100, 120, 130 and 150 °C). To analyze the reaction mixture and to determine radiochemical 
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yields, samples were taken for radio-HPLC and radio-TLC at different time points (5, 10, 15, 20 
and 25 min).  
 
4.2.2.2. Automated syntheses with tosylate 27 as precursor 
Remote controlled radiosynthesis of [18F]7 was performed using a TRACERlab FX2 N 
synthesizer (GE Healthcare, USA) equipped with a Laboport vacuum pump N810.3FT.18 (KNF 
Neuburger GmbH, Freiburg, Germany), a BlueShadow UV detector 10D (KNAUER GmbH, 
Berlin, Germany) and the TRACERlab FX Software. 
[18F]Fluoride (4 – 5 GBq) was trapped on a Chromafix® 30 PS-HCO3- cartridge (Figure 4, entry 
1, ABX, Radeberg, Germany) and eluted into the reactor with 400 µL of an aqueous solution 
of potassium carbonate (K2CO3, 1.8 mg, 13 µmol, entry 2). After adding Kryptofix 2.2.2. in 1 mL 
of ACN (11 mg, 29 µmol, entry 3), the mixture was azeotropically dried for approximately 10 
minutes. Thereafter, 2.0 - 2.5 mg of the tosylate precursor 27 dissolved in 1 mL of DMSO (entry 
4) was added, and the reaction mixture was stirred at 100 ⁰C for 15 min. After cooling, the 
reaction mixture was diluted with 2.0 mL of H2O and 1.0 mL of ACN (entry 5) and transferred 
into the injection vial (entry 6). Semi-preparative HPLC was performed using a Reprosil-Pur 
C18-AQ column (250 x 10 mm; 10 µm; Dr. Maisch HPLC GmbH, Germany) with a solvent 
composition of 55% ACN/40 mM NH4OAcaq. at a flow rate of 3.5 mL/min (entry 7). [18F]7 was 
collected in the dilution vessel (entry 8) previously loaded with 40 mL of H2O. Final purification 
was performed by passing the solution through a Sep-Pak C18 light cartridge (entry 9), 
followed by washing with 2 mL of water (entry 10) and elution of [18F]7 with 1.2 mL of EtOH 
(entry 11) into the product vial (entry 12). The ethanolic solution was transferred in a 
neighboring hotcell by remote control and the solvent manually reduced under a gentle argon 
stream at 75 ⁰C to a final volume of 10-50 µL. Afterwards the radiotracer was diluted in 
isotonic saline to obtain a final product containing 10% of EtOH (v/v).  
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Figure 4. Scheme of the synthesis module TRACERlab FX2 N for the radiosynthesis of [18F]7.  
Tosylate 27 as precursor: (1) Chromafix 30-PS-HCO3-, (2) K2CO3 (1.8 mg in 400 µL water), (3) K2.2.2. (11 mg in 1 mL 
ACN), (4) precursor (2 mg of 27 in 1 mL DMSO), (5) 2.0 mL water and 1.0 mL ACN, (6) injection vial, (7) Reprosil-
Pur C18-AQ (55% ACN/40 mM NH4OAcaq., flow 3.5 mL/min), (8) 40 mL water, (9) Sep-Pak C18 light, (10) 2 mL 
water, (11) 1.2 mL EtOH, (12) product vial. 
Nosylate 28 as precursor: (1) Sep-Pak Accell QMA light cartridge, (2) 150 µL TBAHCO3 in 300 µl water and 650 
µl ACN, (3) 2 mL ACN, (4) precursor (2 mg of 28 in 200 µL ACN + 700 µL 3M3P + 80 µL water), (5) 2.0 mL water + 
2.0 mL ACN, (6) injection vial, (7) Reprosil-Pur C18-AQ (55% ACN/40 mM NH4OAcaq., flow 2.8 mL/min), (8) 40 mL 
water, (9) Sep-Pak C18 light, (10) 2 mL water, (11) 1.2 mL EtOH, (12) product vial. 
 
4.2.2.3. Manual syntheses with nosylate 28 as precursor 
No carrier added [18F]fluoride in 1.5 mL of water was trapped on a Chromafix® 30 PS-HCO3- 
cartridge (ABX GmbH, Radeberg, Germany). The activity was eluted with 300 µL of an aqueous 
solution of potassium carbonate (K2CO3, 1.8 mg, 13 µmol) into a 4 mL V-vial and Kryptofix 2.2.2 
(K2.2.2, 11 mg, 29 µmol) in 1 mL of ACN was added. For investigations of the precursor to base 
ratio, the amount of potassium carbonate was accordingly reduced or increased. For labeling 
with [18F]TBAF, the tetra-n-butylammonium hydrogene carbonate (TBAHCO3) solution (0.075 
M, ABX, Radeberg, Germany) was directly placed into the V-vial containing [18F]fluoride and 1 
mL of ACN. The aqueous [18F]fluoride was then azeotropically dried under vacuum and 
nitrogen flow within 7-10 min using a single mode microwave (75 W, at 50  ̶ 60 °C, power 
cycling mode). Two aliquots of ACN (2 x 1.0 mL) were added during the drying procedure and 
the final complex was dissolved in an appropriate volume of labeling solvent and used directly 
or divided in several portions. Thereafter, a solution of 2.0   ̶ 2.5 mg of precursor 28 in 300 - 
500 µL of an appropriate solvent was added, and 18F-labeling was performed at different 
temperatures in dependence of the solvent used (90, 100, 120, 130 and 150 °C). To analyze 
the reaction mixture and to determine radiochemical yields, samples were taken for radio-
HPLC and radio-TLC at different time points (5, 10, 15, 20 and 25 min).  
 
4.2.2.4. Automated syntheses with nosylate 28 as precursor 
Remote controlled radiosynthesis of [18F]7 was performed using a TRACERlab FX2 N 
synthesizer (GE Healthcare, USA) equipped with a Laboport vacuum pump N810.3FT.18 (KNF 
Neuburger GmbH, Freiburg, Germany), a BlueShadow UV detector 10D (KNAUER GmbH, 
Berlin, Germany) and the TRACERlab FX Software. 
[18F]Fluoride (4 – 5 GBq) was trapped on a Sep-Pak Accell QMA light cartridge (Figure 5, entry 
1, Waters, USA) and eluted into the reactor with a solution of 150 µL of TBAHCO3  (entry 2, 
0.075 M, ABX GmbH, Radeberg, Germany), 300 µL of water and 650 µL of ACN. After 
azeotropic drying at 50 °C for 3 min, 2 mL ACN (entry 3) were added and azeotropic drying was 
continued for further 3 min at 70 °C and 1 min at 40 °C. Thereafter, 2.0   ̶ 2.5 mg of the nosylate 
precursor (28) dissolved in a mixture of 200 µL ACN / 700 µL 3M3P / 80 µL water (entry 4) was 
added, and the reaction mixture was stirred at 125 °C for 10 min. After cooling to 40 °C, the 
solvent was evaporated under vacuum and helium stream for 7 min, the residue was diluted 
with 2.0 mL of H2O and 2.0 mL of ACN (entry 5) and transferred into the injection vial (entry 
6). Semi-preparative HPLC was performed using a Reprosil-Pur C18-AQ column (250 x 10 mm; 
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10 µm; Dr. Maisch HPLC GmbH; Germany) with a solvent composition of 55% ACN/40 mM 
NH4OAcaq. at a flow rate of 2.8 mL/min (entry 7). [18F]7 was collected in the dilution vessel 
(entry 8) previously loaded with 40 mL of H2O. Final purification was performed by passing the 
solution through a Sep-Pak C18 light cartridge (entry 9), followed by washing with 2 mL of 
water (entry 10) and elution of [18F]7 with 1.2 mL of EtOH (entry 11) into the product vial 
(entry 12). The ethanolic solution was transferred in a neighboring hotcell by remote control 
and the solvent manually reduced under a gentle argon stream at 75 °C to a final volume of 
10-50 µL. Afterwards the radiotracer was diluted in isotonic saline to obtain a final product 
containing 10% of EtOH (v/v). 
 
4.2.2.5. In vitro stability  
The in vitro stability of [18F]7 was investigated by incubation of small tracer amounts (~ 5 MBq) 
at 40 °C in 500 µL of phosphate buffered saline and 500 µL of pig plasma samples. After 30 
and 60 minutes, aliquots were taken and analyzed by radio-TLC and radio-HPLC.  
 
4.3. In vitro autoradiographic studies of [18F]7 
Brain sections (20 μm) of flash-frozen brains of female domestic pigs (Sus s. domestica, 6 
weeks, 12–14 kg) were cut using a cryostat, thaw-mounted onto microscope slides, and after 
air-drying stored at –80 °C until use. Briefly, the brain sections were allowed to thaw in air, 
and pre-incubated once in 50 mM TRIS buffer (pH 7.4) to remove endogenous ligand. The 
sections were then incubated with 2.02 ± 0.75 nM of [18F]7 in TRIS buffer (50 mM TRIS-HCl, 
120 mM NaCl, 5 mM KCl, 2 mM MgCl2, 2 mM CaCl2, 0.1% BSA pH 7.4) for 60 minutes at room 
temperature. Nonspecific binding was determined in the presence of 1 μM 7. Displacement 
of [18F]7 was also evaluated with 1 µM sildenafil. Subsequently, the sections were washed 
twice for 2 minutes in ice-cold TRIS buffer, and dipped for 5 seconds in ice-cold distilled water. 
The sections were rapidly dried in a stream of cold air before being exposed to an imaging 
plate. Developed autoradiographs were analysed in a phosphor imager (Fuji BAS 1800 II). The 
quantification was performed by using 2D-densitometric analysis (AIDA 2.31 software; raytest 
Isotopenmessgeräte GmbH, Germany). 
 
4.4. In vivo studies of [18F]7 in mice 
All animal studies followed the international guidelines of animal care and the study protocols 
were approved by the Landesdirektion Leipzig, the local authority for animal care (Reg.-Nr.: 
TVV 08/13; Reference number: 24-9168.11/18/8). All animal experiments were performed 
with female CD-1 mice, 10-12 weeks old, obtained from the Experimental Centre of the Faculty 
of Medicine (MEZ) at the Leipzig University, Leipzig, Germany. 
 
4.4.1 Organ uptake 
[18F]7 obtained as described in 4.2.2.4. was dissolved in 200 µL of sterile isotonic saline and 
administered as a bolus injection via the tail vein of the restrained animal. At 5 (n=1; dose: 
0.61 MBq) and 30 minutes p.i. (n=2; dose: 38 and 49 MBq), retro-orbital blood samples were 
obtained from the anesthetized animals. Immediately afterwards, organs of interest were 
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isolated and blood plasma was obtained by centrifugation of the whole blood sample (15000 
rpm, room temperature, 1 minute). All samples were weighed and the radioactivity (in CPM) 
was measured in a gamma-counter (Wizard 2480, PerkinElmer LAS GmbH, Germany). For 
conversion of CPM values to Bq, standard samples were measured in a dose calibrator 
(ISOMED 2010, MED Nuklear-Medizintechnik Dresden GmbH, Dresden, Germany) as well as 
by gamma-counting. For each sample, the percentage of the injected dose was calculated and 
normalized according to the tissue weight (% ID/gtissue), followed by normalization according 
to the injected dose and the weight of the animal [(% ID/gtissue)/(100 %/ganimal)] to calculate 
the standardized uptake value (SUV) for each tissue. 
 
4.4.2. Metabolism studies  
Mouse blood samples were taken at 30 minutes after intravenous injection of ~40 MBq of 
[18F]7 (n = 2). Plasma was obtained by centrifugation of blood at 12,000 rpm at room 
temperature for 1 minute.  
MLC: For preparation of the MLC injection samples, mouse plasma (20 – 50 µL, 30 minutes 
p.i.) was dissolved in 100 – 300 µL of 100 mM aqueous sodium dodecyl sulfate (SDS). 
Homogenized brain material (200 µL, 30 minutes p.i.) was dissolved in 400 µL of 200 mM 
aqueous SDS, stirred at 75 °C for 5 minutes, diluted with more 200 µL of 200 mM aqueous SDS 
and injected into the MLC system after cooling to room temperature. To proof the integrity of 
the radioligand under these conditions, 50 kBq of the radioligand were stirred at 75 °C for 5 
minutes in 500 µL of 200 mM aqueous SDS and analysed via MLC. The MLC system was built 
up of a JASCO PU-980 pump, an AS-2055Plus auto injector with a 2000 L sample loop, and a 
UV-1575 detector coupled with a gamma radioactivity HPLC detector (Gabi Star, raytest 
Isotopenmessgeräte GmbH). Data analysis was performed with the Galaxie chromatography 
software (Agilent Technologies). A Reprosil-Pur C18-AQ column (250 x 4.6 mm, particle size: 
10 µm) coupled with a pre-column of 10 mm length was used. Separations were performed by 
using an eluent mixture of THF/100 mM aqueous SDS/10 mM Na2HPO4 aq. in gradient mode 
(0 – 10 min at 5% THF, 10 – 25 min up to 50% THF, 25 – 30 min at 50% THF, 30 – 31 min up to 
5% THF; 31 – 40 min at 5% THF/100 mM SDS aq., 10 mM Na2HPO4 aq.) at a flow rate of 1.0 
mL/min.  
RP-HPLC: For protein precipitation and extraction an ice-cold mixture of acetone/water (9/1; 
v/v) was used in a ratio of 4 : 1 of solvent to plasma or brain homogenate, respectively. The 
samples were vortexed for 2 minutes, equilibrated on ice for 10 minutes, and centrifuged for 
5 minutes at 10,000 rpm. After separating the supernatant, the precipitates were washed with 
200 µL of the solvent mixture and subjected to the same procedure. The combined 
supernatants (total volume between 1.0 –1.5 mL) were concentrated at 65 °C under nitrogen 
flow to a final volume of approximately 100 µL and analyzed by analytical radio-HPLC. To 
determine the percentage of radioactivity in the supernatants compared to total activity, 
aliquots of each step as well as the precipitates were quantified by  counting (PerkinElmer 
Wallac Wizard 1480 Gamma Counter, manufactured by WALLAC, Turku, Finland). With this 
procedure, recoveries of about 97% for the plasma and brain homogenates could be obtained. 
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To analyse the worked-up samples, the same HPLC method was used as described in the 
radiochemistry part. 
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